BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schömig A, Pfisterer ME, Stone GW, Leon MB, de Lezo JS. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet. 2007;370:937-948. [PMID: 17869634 DOI: 10.1016/s0140-6736(07)61444-5] [Cited by in Crossref: 1070] [Cited by in F6Publishing: 209] [Article Influence: 71.3] [Reference Citation Analysis]
Number Citing Articles
1 Ho HH, Pong V, Siu CW, Jim MH, Miu R, Yiu KH, Ko R, Tse HF, Kwok OH, Chow WH. Long-term clinical outcomes of drug-eluting stents vs bare-metal stents in Chinese patients. Clin Cardiol 2010;33:E22-9. [PMID: 20556818 DOI: 10.1002/clc.20655] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
2 Mauri L, Kereiakes DJ, Normand SL, Wiviott SD, Cohen DJ, Holmes DR, Bangalore S, Cutlip DE, Pencina M, Massaro JM. Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions. Am Heart J 2010;160:1035-41, 1041.e1. [PMID: 21146655 DOI: 10.1016/j.ahj.2010.07.038] [Cited by in Crossref: 131] [Cited by in F6Publishing: 121] [Article Influence: 10.9] [Reference Citation Analysis]
3 Ward TJ, Lookstein RA. Drug-eluting stents for infrapopliteal arterial disease in the setting of critical limb ischemia. Expert Rev Cardiovasc Ther 2011;9:1339-46. [PMID: 21985546 DOI: 10.1586/erc.11.125] [Reference Citation Analysis]
4 Li JM, Newburger PE, Gounis MJ, Dargon P, Zhang X, Messina LM. Local arterial nanoparticle delivery of siRNA for NOX2 knockdown to prevent restenosis in an atherosclerotic rat model. Gene Ther 2010;17:1279-87. [PMID: 20485380 DOI: 10.1038/gt.2010.69] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
5 Lim KS, Park J, Jeong MH, Bae I, Nah J, Park DS, Sim J, Kim JH, Lee SY, Jang EJ, Jang S, Kim HK, Sim DS, Kim IS, Hong YJ, Ahn Y, Kang JC. Optimal coating method for a dual-layer stent with sirolimus and alpha-lipoic acid in a porcine coronary restenosis model. Macromol Res 2016;24:725-33. [DOI: 10.1007/s13233-016-4082-9] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
6 Matsuda H, Suzuki Y. Long-term (beyond 5 years) clinical impact of Xience everolimus-eluting stent implantation. Health Sci Rep 2021;4:e365. [PMID: 34522790 DOI: 10.1002/hsr2.365] [Reference Citation Analysis]
7 Moreno R, Legrand V, Ferrario M, MacCarthy P, Redwood S, Werner N, Jung W, Ungi I, Zaman A, Richardt G, Crowley J, Schwimmbeck P, Christen T, Allocco DJ, Meredith IT. Clinical outcomes in unselected patients treated with the PROMUS Element platinum-chromium, everolimus-eluting stent: Final five-year results from the PE PROVE Study. Catheter Cardiovasc Interv 2019;93:398-403. [PMID: 30341836 DOI: 10.1002/ccd.27835] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Tortora M, Gemini L, D’iglio I, Ugga L, Spadarella G, Cuocolo R. Spectral Photon-Counting Computed Tomography: A Review on Technical Principles and Clinical Applications. J Imaging 2022;8:112. [DOI: 10.3390/jimaging8040112] [Reference Citation Analysis]
9 Liu SW, Qiao SB, Xu B, Hu FH, Chen J, Yuan JQ, Wu YJ, Yang YJ, Chen JL, Gao RL. Outcomes of overlapping heterogeneous drug-eluting stents versus homogeneous drug-eluting stents for diffuse lesions in small coronary arteries. J Interv Cardiol 2013;26:264-70. [PMID: 23488819 DOI: 10.1111/j.1540-8183.2013.12023.x] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
10 Prasad A, Rihal C, Holmes DR Jr. The COURAGE trial in perspective. Catheter Cardiovasc Interv 2008;72:54-9. [PMID: 18412271 DOI: 10.1002/ccd.21522] [Reference Citation Analysis]
11 Nakazato K, Mizukami H, Ohtake H, Sakamoto N, Yamaki T, Yamaguchi O, Kunii H, Ohwada T, Takeishi Y. STENTING STRATEGY AND FOLLOW-UP RESULTS OF MULTI-CENTER REGISTRY IN FUKUSHIMA CITY FOR LEFT MAIN CORONARY ARTERY DISEASE: BARE METAL STENT VERSUS DRUG-ELUTING STENT. Fukushima J Med Sci 2015;61:79-85. [PMID: 26135665 DOI: 10.5387/fms.2015-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
12 Kafkas N, Dragasis S. Current knowledge on very late stent thrombosis. Cont Cardiol Educ 2018;4:40-4. [DOI: 10.1002/cce2.75] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Zhu Z, Wang Y, Liao W, Li H, Wang D. Effect of various Danshen injections on patients with coronary heart disease after percutaneous coronary intervention: A protocol for a systematic review and network meta-analysis. Medicine (Baltimore) 2018;97:e11062. [PMID: 29901609 DOI: 10.1097/MD.0000000000011062] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
14 Katz G, Harchandani B, Shah B. Drug-eluting stents: the past, present, and future. Curr Atheroscler Rep 2015;17:485. [PMID: 25651784 DOI: 10.1007/s11883-014-0485-2] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 3.9] [Reference Citation Analysis]
15 Kim HK, Jeong MH. Coronary stent thrombosis: current insights into new drug-eluting stent designs. Chonnam Med J 2012;48:141-9. [PMID: 23323218 DOI: 10.4068/cmj.2012.48.3.141] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
16 Wykrzykowska JJ, Arbab-Zadeh A, Godoy G, Miller JM, Lin S, Vavere A, Paul N, Niinuma H, Hoe J, Brinker J, Khosa F, Sarwar S, Lima J, Clouse ME. Assessment of in-stent restenosis using 64-MDCT: analysis of the CORE-64 Multicenter International Trial. AJR Am J Roentgenol 2010;194:85-92. [PMID: 20028909 DOI: 10.2214/AJR.09.2652] [Cited by in Crossref: 29] [Cited by in F6Publishing: 6] [Article Influence: 2.4] [Reference Citation Analysis]
17 Munkholm-Larsen S, Yan TD. Percutaneous coronary intervention versus bypass grafting in left main coronary artery disease. J Thorac Dis 2016;8:2677-9. [PMID: 27867541 DOI: 10.21037/jtd.2016.10.50] [Reference Citation Analysis]
18 Ielasi A, Anzuini A. Kissing drug-eluting balloons for the treatment of unprotected distal left main bifurcation drug-eluting stent restenosis. Cardiovasc Revasc Med 2012;13:347-9. [PMID: 23000439 DOI: 10.1016/j.carrev.2012.08.007] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
19 Remkes WS, Badings EA, Hermanides RS, Rasoul S, Dambrink JE, Koopmans PC, The SH, Ottervanger JP, Gosselink AT, Hoorntje JC, Suryapranata H, van 't Hof AW. Randomised comparison of drug-eluting versus bare-metal stenting in patients with non-ST elevation myocardial infarction. Open Heart 2016;3:e000455. [PMID: 27933192 DOI: 10.1136/openhrt-2016-000455] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
20 Wang C, Zhang L, Fang Y, Sun W. Design, Characterization, and 3D Printing of Cardiovascular Stents with Zero Poisson’s Ratio in Longitudinal Deformation. Engineering 2021;7:979-90. [DOI: 10.1016/j.eng.2020.02.013] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 8.0] [Reference Citation Analysis]
21 Velders MA, Hofma SH, Brouwer J, de Vries CJ, Queré M, van Boven AJ. Two-year results of an open-label randomized comparison of everolimus-eluting stents and sirolimus-eluting stents. PLoS One 2014;8:e64424. [PMID: 23755123 DOI: 10.1371/journal.pone.0064424] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
22 De Caro F, De Carlo M, Petronio AS. Optical coherence tomography-guided treatment of very late stent thrombosis caused by inaccurate stent deployment in a bifurcation. J Cardiovasc Med (Hagerstown) 2016;17 Suppl 2:e185-8. [PMID: 25004004 DOI: 10.2459/JCM.0000000000000126] [Reference Citation Analysis]
23 Navarese EP, Austin D, Gurbel PA, Andreotti F, Tantry U, James S, Buffon A, Kozinski M, Obonska K, Bliden K, Jeong YH, Kubica J, Kunadian V. Drug-coated balloons in treatment of in-stent restenosis: a meta-analysis of randomised controlled trials. Clin Res Cardiol 2013;102:279-87. [PMID: 23262495 DOI: 10.1007/s00392-012-0532-3] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
24 Gokay S, Cicek D, Muderrisoglu H. Sirolimus-Versus Zotarolimus-Eluting Stents in Acute Coronary Syndromes With C Type Left Anterior Descending Artery Lesions: A Three-Year Clinical Follow-Up. Cardiol Res 2012;3:116-22. [PMID: 28352407 DOI: 10.4021/cr170w] [Reference Citation Analysis]
25 Chae IH, Yoon CH, Park JJ, Oh IY, Suh JW, Cho YS, Youn TJ, Choi DJ. Comparison of Drug-Eluting Balloon Followed by Bare Metal Stent with Drug-Eluting Stent for Treatment of de Novo Lesions: Randomized, Controlled, Single-Center Clinical Trial. J Korean Med Sci 2017;32:933-41. [PMID: 28480650 DOI: 10.3346/jkms.2017.32.6.933] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
26 Jubran A, Willemink MJ, Nieman K. Coronary CT in Patients with a History of PCI or CABG: Helpful or Harmful? Curr Cardiovasc Imaging Rep 2019;12. [DOI: 10.1007/s12410-019-9496-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
27 Ertaş G, van Beusekom HM, van der Giessen WJ. Late stent thrombosis, endothelialisation and drug-eluting stents. Neth Heart J 2009;17:177-80. [PMID: 19421365 DOI: 10.1007/BF03086242] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
28 Hara M, Nishino M, Taniike M, Makino N, Kato H, Egami Y, Shutta R, Yamaguchi H, Tanouchi J, Yamada Y. High incidence of thrombus formation at 18 months after paclitaxel-eluting stent implantation: angioscopic comparison with sirolimus-eluting stent. Am Heart J 2010;159:905-10. [PMID: 20435203 DOI: 10.1016/j.ahj.2010.02.032] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
29 Dörr R. [Acute coronary syndrome - a challenge for the cooperation between outpatient and inpatient care]. Herz 2008;33:395-401. [PMID: 19156374 DOI: 10.1007/s00059-008-3163-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
30 Koenig O, Nothdurft D, Perle N, Neumann B, Behring A, Degenkolbe I, Walker T, Schlensak C, Wendel HP, Nolte A. An Atelocollagen Coating for Efficient Local Gene Silencing by Using Small Interfering RNA. Mol Ther Nucleic Acids 2017;6:290-301. [PMID: 28325296 DOI: 10.1016/j.omtn.2017.01.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
31 Roleder T, Kedhi E, Berta B, Gasior P, Wanha W, Roleder M, Fluder J, Smolka G, Ochala A, Wojakowski W. Short-term stent coverage of second-generation zotarolimus-eluting durable polymer stents: Onyx one-month optical coherence tomography study. Postepy Kardiol Interwencyjnej 2019;15:143-50. [PMID: 31497046 DOI: 10.5114/aic.2019.86009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
32 Chen D, Tao X, Wang Y, Tian F, Wei Y, Chen G, Shen H, Wang Z, Yu Z, Li H, Chen G. Curcumin accelerates reendothelialization and ameliorates intimal hyperplasia in balloon-injured rat carotid artery via the upregulation of endothelial cell autophagy. Int J Mol Med 2015;36:1563-71. [PMID: 26459716 DOI: 10.3892/ijmm.2015.2365] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
33 Yano H, Horinaka S, Watahik M, Watanabe T, Ishimitsu T. Comparison of the vessel healing process after everolimus-eluting stent and bare metal stent implantations in patients with ST-elevation myocardial infarction. Heart Vessels 2019;34:572-82. [PMID: 30392104 DOI: 10.1007/s00380-018-1287-1] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
34 Nishio K, Hosaka M, Shigemitsu M, Kobayashi Y. Three-year clinical outcome in type 2 diabetic patients with drug-eluting stents versus bare-metal stents with pioglitazone. Cardiovasc Revasc Med 2011;12:197-202. [PMID: 21489889 DOI: 10.1016/j.carrev.2009.10.003] [Reference Citation Analysis]
35 Yu M, Lu Z, Li W, Wei M, Yan J, Zhang J. Coronary plaque characteristics on baseline CT predict the need for late revascularization in symptomatic patients after percutaneous intervention. Eur Radiol 2018;28:3441-53. [PMID: 29450719 DOI: 10.1007/s00330-018-5320-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
36 Stefanadis C. Are drug-eluting stents safe in the long term after saphenous vein graft intervention?: lessons learned from real-world practice. J Am Coll Cardiol 2014;64:1837-9. [PMID: 25443707 DOI: 10.1016/j.jacc.2014.07.980] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
37 Sinha N, Rai H, Cassese S, Kumar S, Kapoor A, Kastrati A. Long-term clinical impact of polymer-free sirolimus-eluting stents in unselected patients. Coron Artery Dis 2016;27:385-90. [PMID: 27124380 DOI: 10.1097/MCA.0000000000000378] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
38 Sakamoto N, Nakazato K, Misaka T, Mizukami H, Kunii H, Suzuki H, Saitoh S, Takeishi Y. Very late stent thrombosis and neointimal plaque rupture after implantation of sirolimus-eluting stents: observations with angiography, IVUS and OCT. Cardiovasc Interv and Ther 2011;26:263-8. [DOI: 10.1007/s12928-011-0064-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
39 Sambola A, García-Dorado D. Dual or triple therapy in patients with atrial fibrillation and drug-eluting stents? Coron Artery Dis 2015;26:367-8. [PMID: 25955251 DOI: 10.1097/MCA.0000000000000257] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
40 Choi YJ, Kim JB, Cho SJ, Cho J, Sohn J, Cho SK, Ha KH, Kim C. Changes in the Practice of Coronary Revascularization between 2006 and 2010 in the Republic of Korea. Yonsei Med J 2015;56:895-903. [PMID: 26069109 DOI: 10.3349/ymj.2015.56.4.895] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
41 Navarese EP, Gurbel PA, Andreotti F, Kołodziejczak MM, Palmer SC, Dias S, Buffon A, Kubica J, Kowalewski M, Jadczyk T, Laskiewicz M, Jędrzejek M, Brockmeyer M, Airoldi F, Ruospo M, De Servi S, Wojakowski W, O' Connor C, Strippoli GF. Prevention of contrast-induced acute kidney injury in patients undergoing cardiovascular procedures-a systematic review and network meta-analysis. PLoS One 2017;12:e0168726. [PMID: 28151965 DOI: 10.1371/journal.pone.0168726] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.6] [Reference Citation Analysis]
42 Morrison DA. Another small step for small vessels. Catheter Cardiovasc Interv 2010;76:67-9. [PMID: 20578195 DOI: 10.1002/ccd.22686] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
43 Hiremath MS. Evaluation and efficacy of long length Pronova XR Bioabsorbable Polymer stent in the treatment of long coronary lesions. Indian Heart J 2017;69:690-4. [PMID: 29174243 DOI: 10.1016/j.ihj.2017.05.002] [Reference Citation Analysis]
44 Kim J, Kim MK, Choi GJ, Shin HY, Kim BG, Kang H. Pharmacological and non-pharmacological strategies for preventing postherpetic neuralgia: a systematic review and network meta-analysis. Korean J Pain 2021;34:509-33. [PMID: 34593669 DOI: 10.3344/kjp.2021.34.4.509] [Reference Citation Analysis]
45 Mishkel GJ, Moore AL, Markwell S, Shelton ME. Correlates of late and very late thrombosis of drug eluting stents. Am Heart J 2008;156:141-7. [PMID: 18585509 DOI: 10.1016/j.ahj.2008.02.012] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
46 Rana JS, Venkitachalam L, Selzer F, Mulukutla SR, Marroquin OC, Laskey WK, Holper EM, Srinivas VS, Kip KE, Kelsey SF, Nesto RW; NHLBI-sponsored PTCA and Dynamic Registries Investigators. Evolution of percutaneous coronary intervention in patients with diabetes: a report from the National Heart, Lung, and Blood Institute-sponsored PTCA (1985-1986) and Dynamic (1997-2006) Registries. Diabetes Care 2010;33:1976-82. [PMID: 20519661 DOI: 10.2337/dc10-0247] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
47 da Costa BR, Pereira TV, Saadat P, Rudnicki M, Iskander SM, Bodmer NS, Bobos P, Gao L, Kiyomoto HD, Montezuma T, Almeida MO, Cheng PS, Hincapié CA, Hari R, Sutton AJ, Tugwell P, Hawker GA, Jüni P. Effectiveness and safety of non-steroidal anti-inflammatory drugs and opioid treatment for knee and hip osteoarthritis: network meta-analysis. BMJ 2021;375:n2321. [PMID: 34642179 DOI: 10.1136/bmj.n2321] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Dash D. Recent perspective on coronary artery bifurcation interventions. Heart Asia 2014;6:18-25. [PMID: 27326157 DOI: 10.1136/heartasia-2013-010451] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
49 Yao Y, Hu Z, Ye J, Hu C, Song Q, Da X, Yu Y, Li H, Xu C, Chen Q, Wang QK. Targeting AGGF1 (angiogenic factor with G patch and FHA domains 1) for Blocking Neointimal Formation After Vascular Injury. J Am Heart Assoc 2017;6:e005889. [PMID: 28649088 DOI: 10.1161/JAHA.117.005889] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
50 Tomaniak M, Kołtowski Ł, Pietrasik A, Rdzanek A, Jąkała J, Proniewska K, Malinowski K, Mazurek T, Filipiak KJ, Brugaletta S, Opolski G, Kochman J. A serial 3- and 9-year optical coherence tomography assessment of vascular healing response to sirolimus- and paclitaxel-eluting stents. Int J Cardiovasc Imaging 2019;35:9-21. [PMID: 30168010 DOI: 10.1007/s10554-018-1437-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
51 Park SD, Yoon CH, Oh IY, Suh JW, Cho YS, Youn TJ, Choi DJ, Chae IH. Comparison of a drug-eluting balloon first and then bare metal stent with a drug-eluting stent for treatment of de novo lesions: study protocol of a randomized controlled trial. Trials 2013;14:38. [PMID: 23394404 DOI: 10.1186/1745-6215-14-38] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
52 Fam JM, Khoo CY, Lau YH, Lye WK, Cai XJ, Choong LHL, Allen JC, Yeo KK. Age and diabetes mellitus associated with worse outcomes after percutaneous coronary intervention in a multi-ethnic Asian dialysis patient population. Singapore Med J 2021;62:300-4. [PMID: 32179924 DOI: 10.11622/smedj.2020025] [Reference Citation Analysis]
53 O'Brien CC, Kolachalama VB, Barber TJ, Simmons A, Edelman ER. Impact of flow pulsatility on arterial drug distribution in stent-based therapy. J Control Release 2013;168:115-24. [PMID: 23541929 DOI: 10.1016/j.jconrel.2013.03.014] [Cited by in Crossref: 34] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
54 Farshidi H, Abdi A, Madani A, Moshiri S, Ghasemi A, Hakimian R. Major adverse cardiovascular event (MACE) after percutaneous coronary intervention in one-year follow-up study. Electron Physician 2018;10:6383-9. [PMID: 29629063 DOI: 10.19082/6383] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
55 Schulz S, Mehilli J, Ndrepepa G, Dotzer F, Dommasch M, Kufner S, Birkmeier KA, Tiroch K, Byrne RA, Schömig A, Kastrati A. Influence of abciximab on evolution of left ventricular function in patients with non-ST-segment elevation acute coronary syndromes undergoing PCI after clopidogrel pretreatment: lessons from the ISAR-REACT 2 trial. Clin Res Cardiol 2011;100:691-9. [PMID: 21384174 DOI: 10.1007/s00392-011-0299-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
56 Hayashi S, Yamamoto A, You F, Yamashita K, Ikegame Y, Tawada M, Yoshimori T, Shimizu S, Nakashima S. The stent-eluting drugs sirolimus and paclitaxel suppress healing of the endothelium by induction of autophagy. Am J Pathol 2009;175:2226-34. [PMID: 19815708 DOI: 10.2353/ajpath.2009.090152] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 3.1] [Reference Citation Analysis]
57 Imani SM, Goudarzi A, Valipour P, Barzegar M, Mahdinejad J, Ghasemi SE. Application of finite element method to comparing the NIR stent with the multi-link stent for narrowings in coronary arteries. Acta Mechanica Solida Sinica 2015;28:605-12. [DOI: 10.1016/s0894-9166(15)30053-7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 12] [Article Influence: 3.6] [Reference Citation Analysis]
58 Ko YG, Kim DM, Cho JM, Choi SY, Yoon JH, Kim JS, Kim BK, Choi D, Jang Y, Hong MK. Optical coherence tomography findings of very late stent thrombosis after drug-eluting stent implantation. Int J Cardiovasc Imaging 2012;28:715-23. [PMID: 21656060 DOI: 10.1007/s10554-011-9905-3] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
59 Lee KH, Jeong MH, Ahn Y, Cho MC, Kim CJ, Kim YJ. New horizons of acute myocardial infarction: from the Korea Acute Myocardial Infarction Registry. J Korean Med Sci 2013;28:173-80. [PMID: 23399991 DOI: 10.3346/jkms.2013.28.2.173] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
60 Finney AC, Orr AW. Guidance Molecules in Vascular Smooth Muscle. Front Physiol 2018;9:1311. [PMID: 30283356 DOI: 10.3389/fphys.2018.01311] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
61 Leung CC, Ball TC, Sidhu MS, DeVries JT, Jayne JE, Robb JF, Kaplan AV, Brown JR, Malenka DJ, Thompson CA. Real World Application of Stenting of Unprotected Left Main Coronary Stenosis: A Single-Center Experience. Cardiol Res 2012;3:100-8. [PMID: 28352405 DOI: 10.4021/cr165w] [Reference Citation Analysis]
62 Lee JH, Jo SM, Jo KD, Kim MK, Lee SY, You SH. Comparison of Drug-eluting Coronary Stents, Bare Coronary Stents and Self-expanding Stents in Angioplasty of Middle Cerebral Artery Stenoses. J Cerebrovasc Endovasc Neurosurg 2013;15:85-95. [PMID: 23844352 DOI: 10.7461/jcen.2013.15.2.85] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
63 Zwart B, van Werkum JW, Heestermans AACM, ten Berg JM. Coronary Stent Thrombosis in the Current Era: Challenges and Opportunities for Treatment. Curr Treat Options Cardio Med 2010;12:46-57. [DOI: 10.1007/s11936-009-0055-z] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
64 Ruiz-Esparza GU, Flores-Arredondo JH, Segura-Ibarra V, Torre-Amione G, Ferrari M, Blanco E, Serda RE. The physiology of cardiovascular disease and innovative liposomal platforms for therapy. Int J Nanomedicine 2013;8:629-40. [PMID: 23413209 DOI: 10.2147/IJN.S30599] [Cited by in Crossref: 6] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
65 Möllmann H, Szardien S, Kempfert J, Nef H, Liebetrau C, Walther T, Hamm C. [Myocardial revascularization]. Herz 2013;38:513-26; quiz 527-8. [PMID: 23897600 DOI: 10.1007/s00059-013-3917-9] [Reference Citation Analysis]
66 Schlitt A, Jámbor C, Spannagl M, Gogarten W, Schilling T, Zwissler B. The perioperative management of treatment with anticoagulants and platelet aggregation inhibitors. Dtsch Arztebl Int 2013;110:525-32. [PMID: 24069073 DOI: 10.3238/arztebl.2013.0525] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
67 Ajmera P, Pothineni R, Chawla KK, Mantravadi SS, Jariwala PV, Vijan V, Vijan V. Real-World Use Of Ultrathin-Strut Biodegradable Polymer-Coated Sirolimus-Eluting Stents In Patients With Coronary Artery Disease: 6-Month Clinical Outcomes. Vasc Health Risk Manag 2019;15:439-47. [PMID: 31695399 DOI: 10.2147/VHRM.S200699] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
68 Stella PR, Pavlakis G, Agostoni P, Nathoe HM, Hoseyni Guyomi S, Hamer BJ, Wildbergh TX, Doevendans PA, Van Belle E. One-year clinical follow-up of a registry evaluating a percutaneous revascularisation strategy combining a pre-specified simple selection process with the use of a new thin-strut bare cobalt-chromium stent. Neth Heart J 2010;18:486-92. [PMID: 20978593 DOI: 10.1007/BF03091820] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
69 Gottesman RF, McKhann GM, Hogue CW. Neurological complications of cardiac surgery. Semin Neurol 2008;28:703-15. [PMID: 19115176 DOI: 10.1055/s-0028-1105973] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
70 Wijns W, Braunwald E; European Society of Cardiology. Advancing the knowledge base on the efficacy-safety ratio with drug-eluting stents contributions from the European Society of Cardiology Congress, Vienna, Austria, September 1-5, 2007. J Am Coll Cardiol 2007;50:2431-3. [PMID: 18154970 DOI: 10.1016/j.jacc.2007.10.012] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
71 Basalus MW, Tandjung K, van Houwelingen KG, Stoel MG, de Man FH, Louwerenburg JW, Saïd SA, Linssen GC, Kleijne MA, van der Palen J, Huisman J, Verhorst PM, von Birgelen C. TWENTE Study: The Real-World Endeavor Resolute Versus Xience V Drug-Eluting Stent Study in Twente: study design, rationale and objectives. Neth Heart J 2010;18:360-4. [PMID: 20730003 DOI: 10.1007/BF03091792] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
72 Bramlage P, Cuneo A, Zeymer U, Hochadel M, Richardt G, Silber S, Senges J, Nienaber CA, Tebbe U, Kuck KH. Prognosis of patients with atrial fibrillation undergoing percutaneous coronary intervention receiving drug eluting stents. Clin Res Cardiol 2013;102:289-97. [PMID: 23291664 DOI: 10.1007/s00392-012-0533-2] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
73 Yu Q, Zhu Z, Liu Y, Zhang J, Li K. Efficacy and Safety of HER2-Targeted Agents for Breast Cancer with HER2-Overexpression: A Network Meta-Analysis. PLoS One 2015;10:e0127404. [PMID: 25993646 DOI: 10.1371/journal.pone.0127404] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
74 Weiss S, Weintraub W. Revascularization vs. Medical Therapy in Stable Ischemic Heart Disease. Prog Cardiovasc Dis 2015;58:299-305. [PMID: 26206111 DOI: 10.1016/j.pcad.2015.07.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
75 Tryfonos A, Green DJ, Dawson EA. Effects of Catheterization on Artery Function and Health: When Should Patients Start Exercising Following Their Coronary Intervention? Sports Med 2019;49:397-416. [PMID: 30719682 DOI: 10.1007/s40279-019-01055-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
76 Barone-Rochette G. The hyperdeliverability of the latest evolution of drug-eluting stents should not cause any steps to be omitted during percutaneous coronary intervention. Arch Cardiovasc Dis 2021;114:609-11. [PMID: 34548265 DOI: 10.1016/j.acvd.2021.08.001] [Reference Citation Analysis]
77 Zhang Q, Zhang R, Shen J, Zhang J, Hu J, Yang Z, Zhang X, Zheng A, Shen W. Impact of admission creatinine level on clinical outcomes of patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention with drug-eluting stent implantation: . Chinese Medical Journal 2008;121:2379-83. [DOI: 10.1097/00029330-200812010-00003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
78 Rodríguez AE, Fernández-Pereira C, Rodríguez-Granillo AM. Changes in the safety paradigm with percutaneous coronary interventions in the modern era: Lessons learned from the ASCERT registry. World J Cardiol 2012; 4(8): 242-249 [PMID: 22953021 DOI: 10.4330/wjc.v4.i8.242] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
79 Petersen JL, Barron JJ, Hammill BG, Cziraky MJ, Anstrom KJ, Wahl PM, Eisenstein EL, Krucoff MW, Califf RM, Schulman KA, Curtis LH. Clopidogrel use and clinical events after drug-eluting stent implantation: findings from the HealthCore Integrated Research Database. Am Heart J 2010;159:462-470.e1. [PMID: 20211310 DOI: 10.1016/j.ahj.2009.11.031] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
80 Villard JW, Paranjape AS, Victor DA, Feldman MD. Applications of optical coherence tomography in cardiovascular medicine, Part 2. J Nucl Cardiol 2009;16:620-39. [PMID: 19479314 DOI: 10.1007/s12350-009-9100-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
81 Pellegrini DO, Gomes VO, Lasevitch R, Smidt L, Azeredo MA, Ledur P, Bodanese R, Sinnott L, Moriguchi E, Caramori P. Efficacy and safety of drug-eluting stents in the real world: 8-year follow-up. Arq Bras Cardiol 2014;103:174-82. [PMID: 25098375 DOI: 10.5935/abc.20140110] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
82 Lim KS, Park JK, Jeong MH, Bae IH, Nah JW, Park DS, Kim JM, Kim JH, Lee SY, Jang EJ, Jang S, Kim HK, Sim DS, Park KH, Hong YJ, Ahn Y, Kang JC. Effect of stents coated with a combination of sirolimus and alpha-lipoic acid in a porcine coronary restenosis model. J Mater Sci Mater Med 2016;27:66. [PMID: 26886814 DOI: 10.1007/s10856-015-5622-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
83 Coughlan JJ, Maeng M, Räber L, Brugaletta S, Aytekin A, Okkels Jensen L, Bär S, Ortega-paz L, Laugwitz K, Madsen M, Heg D, Sabaté M, Kufner S, Warnakula Olesen KK, Kastrati A, Windecker S, Cassese S. Trombosis del stent 10 años después de la intervención coronaria percutánea con stents nuevos frente a stents de la primera generación. Observaciones del metanálisis DECADE. Revista Española de Cardiología 2022. [DOI: 10.1016/j.recesp.2022.02.003] [Reference Citation Analysis]
84 Shimokado A, Kubo T, Utsunomiya H, Yamasaki H, Tanimoto T, Ino Y, Liu Y, Teraguchi I, Ozaki Y, Shiono Y, Orii M, Shimamura K, Yamano T, Yamaguchi T, Hirata K, Imanishi T, Akasaka T. Scanning electron microscopic analysis of polymer damage in drug-eluting stents during multiple stenting. Int J Cardiovasc Imaging 2013;29:1909-13. [PMID: 24030293 DOI: 10.1007/s10554-013-0289-4] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
85 Ahn E, Choi G, Kang H, Baek C, Jung Y, Woo Y, Bang S. Supraglottic airway devices as a strategy for unassisted tracheal intubation: A network meta-analysis. PLoS One 2018;13:e0206804. [PMID: 30395614 DOI: 10.1371/journal.pone.0206804] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
86 Alraies MC, Darmoch F, Tummala R, Waksman R. Diagnosis and management challenges of in-stent restenosis in coronary arteries. World J Cardiol 2017; 9(8): 640-651 [PMID: 28932353 DOI: 10.4330/wjc.v9.i8.640] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 5.8] [Reference Citation Analysis]
87 Rivero F, Cuesta J, Bastante T, García-Guimaraes M, Alfonso F. Treatment options for stent restenosis: insights from intracoronary imaging, clinical trials, and registries. Coron Artery Dis 2017;28:507-17. [PMID: 28562383 DOI: 10.1097/MCA.0000000000000511] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
88 Gad MM, Karrthik AK, Mahmoud AA, Mahmoud AN. Is There a Safety Concern for Drug-Coated Balloons in Peripheral Arterial Disease? Curr Cardiol Rep 2019;21:126. [PMID: 31494770 DOI: 10.1007/s11886-019-1211-z] [Reference Citation Analysis]
89 Shroff GR, Solid CA, Herzog CA. Long-term survival and repeat coronary revascularization in dialysis patients after surgical and percutaneous coronary revascularization with drug-eluting and bare metal stents in the United States. Circulation 2013;127:1861-9. [PMID: 23572500 DOI: 10.1161/CIRCULATIONAHA.112.001264] [Cited by in Crossref: 76] [Cited by in F6Publishing: 31] [Article Influence: 8.4] [Reference Citation Analysis]
90 Kutcher MA. Drug-eluting stents versus bypass surgery for multivessel coronary disease. Curr Cardio Risk Rep 2009;3:331-8. [DOI: 10.1007/s12170-009-0049-0] [Reference Citation Analysis]
91 Jaffery Z, Prasad A, Lee JH, White CJ. Drug-eluting coronary stents - focus on improved patient outcomes. Patient Relat Outcome Meas 2011;2:161-74. [PMID: 22915977 DOI: 10.2147/PROM.S24796] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
92 Goy JJ, Urban P, Kaufmann U, Seydoux C, De Benedetti E, Berger A. Incidence of stent thrombosis and adverse cardiac events 5 years after sirolimus stent implantation in clinical practice. Am Heart J 2009;157:883-8. [PMID: 19376316 DOI: 10.1016/j.ahj.2009.02.007] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
93 Strang AC, Knetsch ML, Koole LH, de Winter RJ, van der Wal AC, de Vries CJ, Tak PP, Bisoendial RJ, Stroes ES, Rotmans JI. Effect of anti-ApoA-I antibody-coating of stents on neointima formation in a rabbit balloon-injury model. PLoS One 2015;10:e0122836. [PMID: 25821966 DOI: 10.1371/journal.pone.0122836] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
94 Douglas G, Van Kampen E, Hale AB, McNeill E, Patel J, Crabtree MJ, Ali Z, Hoerr RA, Alp NJ, Channon KM. Endothelial cell repopulation after stenting determines in-stent neointima formation: effects of bare-metal vs. drug-eluting stents and genetic endothelial cell modification. Eur Heart J 2013;34:3378-88. [PMID: 23008511 DOI: 10.1093/eurheartj/ehs240] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 4.5] [Reference Citation Analysis]
95 Ye Y, Xie H, Zeng Y, Zhao X, Tian Z, Zhang S. Efficacy and safety of biodegradable polymer biolimus-eluting stents versus durable polymer drug-eluting stents: a meta-analysis. PLoS One 2013;8:e78667. [PMID: 24244335 DOI: 10.1371/journal.pone.0078667] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
96 Rahel BM, Laarman GJ, Kelder JC, Ten Berg JM, Suttorp MJ. Three-year clinical outcome after primary stenting of totally occluded native coronary arteries: a randomized comparison of bare-metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions (Primary Stenting of Totally Occluded Native Coronary Arteries [PRISON] II study). Am Heart J 2009;157:149-55. [PMID: 19081412 DOI: 10.1016/j.ahj.2008.08.025] [Cited by in Crossref: 44] [Cited by in F6Publishing: 26] [Article Influence: 3.4] [Reference Citation Analysis]
97 Lim JW, Jeong HS, Hong SJ, Kim HJ, Kim YC, Kang BG, Jeon SM, Cho JY, Lee SH, Joo HJ, Park JH, Yu CW. Effects of lowest-dose vs. highest-dose pitavastatin on coronary neointimal hyperplasia at 12-month follow-up in type 2 diabetic patients with non-ST elevation acute coronary syndrome: an optical coherence tomography analysis. Heart Vessels 2019;34:62-73. [PMID: 30047013 DOI: 10.1007/s00380-018-1227-0] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
98 Dias S, Welton NJ, Sutton AJ, Ades AE. Evidence synthesis for decision making 5: the baseline natural history model. Med Decis Making 2013;33:657-70. [PMID: 23804509 DOI: 10.1177/0272989X13485155] [Cited by in Crossref: 50] [Cited by in F6Publishing: 30] [Article Influence: 6.3] [Reference Citation Analysis]
99 Meng Z, Gao P, Chen L, Peng J, Huang J, Wu M, Chen K, Zhou Z. Artificial Zinc-Finger Transcription Factor of A20 Suppresses Restenosis in Sprague Dawley Rats after Carotid Injury via the PPARα Pathway. Mol Ther Nucleic Acids 2017;8:123-31. [PMID: 28918014 DOI: 10.1016/j.omtn.2017.06.010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
100 Seth A, Chandra P, Chouhan NS, Thakkar AS. A first-in-man study of sirolimus-eluting, biodegradable polymer coated cobalt chromium stent in real life patients. Indian Heart J 2012;64:547-52. [PMID: 23253405 DOI: 10.1016/j.ihj.2012.07.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
101 Jones DP, Patel J. Therapeutic Approaches Targeting Inflammation in Cardiovascular Disorders. Biology (Basel) 2018;7:E49. [PMID: 30453474 DOI: 10.3390/biology7040049] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
102 Pires NM, Jukema JW. Early systemic inflammatory response to drug-eluting stents implantation: the heart of the difference? Editorial to: "Comparison of changes in early inflammatory markers between sirolimus- and paclitaxel-eluting stent implantation" by Li et al. Cardiovasc Drugs Ther 2009;23:103-5. [PMID: 19096920 DOI: 10.1007/s10557-008-6158-z] [Reference Citation Analysis]
103 O'Sullivan JF, Neylon A, Fahy EF, Yang P, McGorrian C, Blake GJ. MiR-93-5p is a novel predictor of coronary in-stent restenosis. Heart Asia 2019;11:e011134. [PMID: 31031831 DOI: 10.1136/heartasia-2018-011134] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
104 Wang PJ, Ferralis N, Conway C, Grossman JC, Edelman ER. Strain-induced accelerated asymmetric spatial degradation of polymeric vascular scaffolds. Proc Natl Acad Sci U S A 2018;115:2640-5. [PMID: 29483243 DOI: 10.1073/pnas.1716420115] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
105 Ma YL, Tang XF, Yao Y, Xu N, Song Y, Jiang P, Xu JJ, Wang HH, Jiang L, Liu R, Zhao XY, Chen J, Gao Z, Qiao SB, Yang YJ, Gao RL, Xu B, Yuan JQ. Comparison of Efficacy and Safety between First- and Second-Generation Drug-Eluting Stents in Patients with Acute Coronary Syndrome. Chin Med J (Engl) 2018;131:1397-405. [PMID: 29893356 DOI: 10.4103/0366-6999.233959] [Reference Citation Analysis]
106 Byrne RA, Joner M, Kastrati A. Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas Grüntzig Lecture ESC 2014. Eur Heart J. 2015;36:3320-3331. [PMID: 26417060 DOI: 10.1093/eurheartj/ehv511] [Cited by in Crossref: 268] [Cited by in F6Publishing: 199] [Article Influence: 38.3] [Reference Citation Analysis]
107 Banifatemeh SA, Sadeghipour P, Alemzadeh-Ansari MJ, Fakhrabadi AA, Zolfaghari F, Zahedmehr A, Mohebbi B, Kiani R, Shakerian F, Rashidinejad A, Hosseini Z, Firouzi A. Role of stent oversizing in patients undergoing primary percutaneous coronary intervention. An open-labeled randomized controlled trial. Minerva Cardiol Angiol 2021;69:513-21. [PMID: 33258566 DOI: 10.23736/S2724-5683.20.05396-7] [Reference Citation Analysis]
108 Li Y, Yu M, Li W, Lu Z, Wei M, Zhang J. Third generation dual-source CT enables accurate diagnosis of coronary restenosis in all size stents with low radiation dose and preserved image quality. Eur Radiol 2018;28:2647-54. [PMID: 29349698 DOI: 10.1007/s00330-017-5256-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
109 Zhang M, Guddeti RR, Matsuzawa Y, Sara JD, Kwon TG, Liu Z, Sun T, Lee SJ, Lennon RJ, Bell MR, Schaff HV, Daly RC, Lerman LO, Lerman A, Locker C. Left Internal Mammary Artery Versus Coronary Stents: Impact on Downstream Coronary Stenoses and Conduit Patency. J Am Heart Assoc 2016;5:e003568. [PMID: 27664803 DOI: 10.1161/JAHA.116.003568] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
110 Baranauskas A, Bajoras V, Budrys P, Laucevičius A, Davidavičius G. FFR guided PCI on long coronary lesions: 2-year clinical results with 2nd or newer generation DES. Acta Med Litu 2016;23:5-10. [PMID: 28356786 DOI: 10.6001/actamedica.v23i1.3264] [Reference Citation Analysis]
111 Cheng CC, Yu FH, Ko PS, Lin HT, Lin WS, Cheng SM, Su SL. Prognostic Analysis of Patients with Acute Myocardial Infarction Undergoing Implantation of Different Stents for the First Time. J Clin Med 2021;10:5093. [PMID: 34768613 DOI: 10.3390/jcm10215093] [Reference Citation Analysis]
112 Alegría-Barrero E, Moreno R. Percutaneous treatment in acute coronary syndromes. World J Cardiol 2011; 3(10): 315-321 [PMID: 22053219 DOI: 10.4330/wjc.v3.i10.315] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
113 Hlatky MA, Boothroyd DB, Baker LC, Go AS. Impact of drug-eluting stents on the comparative effectiveness of coronary artery bypass surgery and percutaneous coronary intervention. Am Heart J 2015;169:149-54. [PMID: 25497260 DOI: 10.1016/j.ahj.2014.10.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
114 Kozel M, Kočka V, Lisa L, Buděšínský T, Toušek P. Immune-inflammatory response after bioresorbable vascular scaffold implantation in patients with acute myocardial infarction with ST elevation in a long-term perspective. Heart Vessels 2019;34:557-63. [PMID: 30315494 DOI: 10.1007/s00380-018-1281-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
115 Stettler C, Allemann S, Wandel S, Kastrati A, Morice MC, Schömig A, Pfisterer ME, Stone GW, Leon MB, de Lezo JS, Goy JJ, Park SJ, Sabaté M, Suttorp MJ, Kelbaek H, Spaulding C, Menichelli M, Vermeersch P, Dirksen MT, Cervinka P, De Carlo M, Erglis A, Chechi T, Ortolani P, Schalij MJ, Diem P, Meier B, Windecker S, Jüni P. Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis. BMJ 2008;337:a1331. [PMID: 18757996 DOI: 10.1136/bmj.a1331] [Cited by in Crossref: 204] [Cited by in F6Publishing: 150] [Article Influence: 14.6] [Reference Citation Analysis]
116 Yang DC, Swaminathan RV, Kim LK, Feldman DN. Pharmacotherapy for the reduction of stent thrombosis. Expert Rev Cardiovasc Ther 2013;11:567-76. [PMID: 23621139 DOI: 10.1586/erc.13.34] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
117 Redfors B, Généreux P, Witzenbichler B, Maehara A, Weisz G, McAndrew T, Mehran R, Kirtane AJ, Stone GW. Percutaneous coronary intervention of lesions with in-stent restenosis: A report from the ADAPT-DES study. Am Heart J 2018;197:142-9. [PMID: 29447774 DOI: 10.1016/j.ahj.2017.11.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
118 Toklu B, Bangalore S. Choosing the right coronary stent in the modern era. Curr Cardiol Rep 2014;16:469. [PMID: 24604695 DOI: 10.1007/s11886-014-0469-4] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
119 Sakhuja R, Bhatt DL. Getting real with drug-eluting stents: 5-year follow up of a real-world cohort. Am Heart J 2009;157:802-4. [PMID: 19376303 DOI: 10.1016/j.ahj.2008.12.022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
120 Alfonso F, Rivero F. Novel sirolimus-eluting stents: back to the future with third-generation drug-eluting stents? Coron Artery Dis 2016;27:80-3. [PMID: 26829456 DOI: 10.1097/MCA.0000000000000337] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
121 Tsai M, Chen C, Chen D, Yang C, Hsieh M, Lee C, Wang C, Chang S, Hsieh I. Review: The outcomes of different vessel diameter in patients receiving coronary artery stenting. International Journal of Cardiology 2016;224:317-22. [DOI: 10.1016/j.ijcard.2016.09.061] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
122 Cho YK, Hur SH, Park NH, Choi SW, Sohn JH, Cho HO, Park HS, Yoon HJ, Kim H, Nam CW, Kim YN, Kim KB. Long-term outcomes of intravascular ultrasound-guided implantation of bare metal stents versus drug-eluting stents in primary percutaneous coronary intervention. Korean J Intern Med 2014;29:66-75. [PMID: 24574835 DOI: 10.3904/kjim.2014.29.1.66] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
123 Rozemeijer R, van Muiden IG, Koudstaal S, Leenders GE, Timmers L, Rittersma SZ, Kraaijeveld AO, Doevendans PA, Voskuil M, Stella PR. One-year clinical outcomes of patients treated with polymer-free amphilimus-eluting stents or zotarolimus-eluting stents: A propensity-score adjusted analysis. Catheter Cardiovasc Interv 2019;94:61-9. [PMID: 30604493 DOI: 10.1002/ccd.28041] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
124 Lee MS, Mahmud E, Ang L, Lluri G, Cheng RK, Aragon J, Sheiban I. Comparison of sirolimus-, paclitaxel-, and everolimus-eluting stent in unprotected left main coronary artery percutaneous coronary intervention. J Saudi Heart Assoc 2013;25:75-8. [PMID: 24174850 DOI: 10.1016/j.jsha.2013.03.001] [Reference Citation Analysis]
125 Runciman WB, Baker GR, Michel P, Jauregui IL, Lilford RJ, Andermann A, Flin R, Weeks WB. The epistemology of patient safety research: . International Journal of Evidence-Based Healthcare 2008;6:476-86. [DOI: 10.1097/01258363-200812000-00008] [Reference Citation Analysis]
126 Ko E, Nasu K, Habara M, Tanaka N, Terashima M, Kinoshita Y, Tsuchikane E, Asakura Y, Katoh O, Suzuki T. Long-term serial angiographic outcomes after sirolimus-eluting stent implantation. Catheter Cardiovasc Interv 2013;81:E29-35. [PMID: 22517538 DOI: 10.1002/ccd.24383] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
127 Trappe H. The SYNTAX study. Clin Res Cardiol Suppl 2010;5:70-4. [DOI: 10.1007/s11789-010-0004-0] [Reference Citation Analysis]
128 Zhang B, Qin Y, Yang L, Wu Y, Chen N, Li M, Li Y, Wan H, Fu D, Luo R, Yuan L, Wang Y. A Polyphenol-Network-Mediated Coating Modulates Inflammation and Vascular Healing on Vascular Stents. ACS Nano 2022. [PMID: 35301848 DOI: 10.1021/acsnano.2c00642] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
129 Liu SW, Xu B, Chen J, Hu FH, Wu YJ, Li JJ, Yang YJ, Chen JL, Gao RL, Qiao SB. Trends in in-hospital outcome after percutaneous coronary intervention in the drug-eluting stents era. Clin Cardiol 2010;33:516-21. [PMID: 20734450 DOI: 10.1002/clc.20786] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
130 Bae S, Kim Y, Gogas BD, Kim MC, Sim DS, Hong YJ, Kim JH, Ahn Y, Jeong MH. Efficacy and safety of drug-eluting stents in elderly patients: A meta-analysis of randomized trials. Cardiol J 2021;28:223-34. [PMID: 31702046 DOI: 10.5603/CJ.a2019.0109] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
131 Colombo A, Ruparelia N. Is a Drug-Eluting Stent the Default Treatment Strategy for Drug-Eluting Stent Restenosis? J Am Coll Cardiol 2015;66:34-6. [PMID: 26139055 DOI: 10.1016/j.jacc.2015.04.055] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
132 Nielsen EE, Feinberg J, Greenhalgh J, Hounsome J, Sethi NJ, Safi S, Gluud C, Jakobsen JC; Cochrane Heart Group. Drug-eluting stents versus bare-metal stents for stable ischaemic heart disease. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd012480] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
133 Sakakura K, Kubo N, Ako J, Ikeda N, Funayama H, Hirahara T, Wada H, Sugawara Y, Yasu T, Kawakami M, Momomura S. Clinical features of early recurrent myocardial infarction. Heart Vessels 2009;24:347-51. [PMID: 19784817 DOI: 10.1007/s00380-008-1133-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
134 Kufner S, Kastrati A. Drug-eluting stents for drug-eluting stent restenosis: stick with the old or switch to a new one? Coron Artery Dis 2014;25:633-5. [PMID: 25365642 DOI: 10.1097/MCA.0000000000000171] [Reference Citation Analysis]
135 Kovacic JC, Lee P, Karajgikar R, Baber U, Narechania B, Suleman J, Moreno PR, Sharma SK, Kini AS. Safety of temporary and permanent suspension of antiplatelet therapy after drug eluting stent implantation in contemporary "real-world" practice. J Interv Cardiol 2012;25:482-92. [PMID: 22724441 DOI: 10.1111/j.1540-8183.2012.00746.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
136 Biswas S, Hristov B, Kinthala S, Abrol S. Post Traumatic Pseudoaneurysm of Left Anterior Descending Artery Presenting as Acute Coronary Syndrome. Cardiol Res 2019;10:114-9. [PMID: 31019641 DOI: 10.14740/cr825] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
137 Franzone A, Heg D, Räber L, Valgimigli M, Piccolo R, Zanchin T, Yamaji K, Stortecky S, Blöchlinger S, Hunziker L, Praz F, Jüni P, Windecker S, Pilgrim T. External validity of the "all-comers" design: insights from the BIOSCIENCE trial. Clin Res Cardiol 2016;105:744-54. [PMID: 27033859 DOI: 10.1007/s00392-016-0983-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
138 Dunlay SM, Rihal CS, Sundt TM, Gerber Y, Roger VL. Current trends in coronary revascularization. Curr Treat Options Cardiovasc Med 2009;11:61-70. [PMID: 19141262 DOI: 10.1007/s11936-009-0007-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
139 Bennett J, Dubois C. A novel platinum chromium everolimus-eluting stent for the treatment of coronary artery disease. Biologics 2013;7:149-59. [PMID: 23818756 DOI: 10.2147/BTT.S34939] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
140 Lee JM, Youn TJ, Park JJ, Oh IY, Yoon CH, Suh JW, Cho YS, Cho GY, Chae IH, Choi DJ. Comparison of 9-month angiographic outcomes of Resolute zotarolimus-eluting and everolimus-eluting stents in a real world setting of coronary intervention in Korea. BMC Cardiovasc Disord 2013;13:65. [PMID: 24011332 DOI: 10.1186/1471-2261-13-65] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
141 Pilgrim T, Roffi M, Tüller D, Muller O, Vuilliomenet A, Cook S, Weilenmann D, Kaiser C, Jamshidi P, Heg D, Jüni P, Windecker S. Randomized comparison of biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents for percutaneous coronary revascularization: rationale and design of the BIOSCIENCE trial. Am Heart J 2014;168:256-61. [PMID: 25173535 DOI: 10.1016/j.ahj.2014.06.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
142 Tandar A, Velagapudi KN, Wilson BD, Boden WE. Perioperative antiplatelet management in patients with coronary artery stenting. Hosp Pract (1995) 2012;40:118-30. [PMID: 22615086 DOI: 10.3810/hp.2012.04.977] [Reference Citation Analysis]
143 Gallego L, Martínez-Sellés M, García E, Franco J, Estévez A, Sarnago Cebada F, Fernández-Avilés F. Characteristics and outcome of angiographically confirmed stent thrombosis. Rev Esp Cardiol 2009;62:220-3. [PMID: 19232197 DOI: 10.1016/s1885-5857(09)71542-7] [Reference Citation Analysis]
144 Head SJ, Hickey GL. Finding the forest through the trees in statistics: let the Statistical Primers in EJCTS/ICVTS guide you. Interact Cardiovasc Thorac Surg 2018;26:537-8. [PMID: 29596694 DOI: 10.1093/icvts/ivy064] [Reference Citation Analysis]
145 Dixon SR, Grines CL, O'Neill WW. The year in interventional cardiology. J Am Coll Cardiol 2008;51:2355-69. [PMID: 18549922 DOI: 10.1016/j.jacc.2008.03.021] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
146 Russ M, Werdan K, Cremer J, Krian A, Meinertz T, Zerkowski HR. Different treatment options in chronic coronary artery disease: when is it the time for medical treatment, percutaneous coronary intervention or aortocoronary bypass surgery? Dtsch Arztebl Int 2009;106:253-61. [PMID: 19547626 DOI: 10.3238/arztebl.2009.0253] [Cited by in Crossref: 4] [Article Influence: 0.3] [Reference Citation Analysis]
147 Warner JL, Yang PC, Alterovitz G. Overcoming the Straw Man Effect in Oncology: Visualization and Ranking of Chemotherapy Regimens Using an Information Theoretic Approach. JCO Clin Cancer Inform 2017;1:1-9. [PMID: 30657401 DOI: 10.1200/CCI.17.00079] [Reference Citation Analysis]
148 Yi Y, Chen J, Hsiang Y, Takahata K. Wirelessly Heating Stents via Radiofrequency Resonance toward Enabling Endovascular Hyperthermia. Adv Healthc Mater 2019;8:e1900708. [PMID: 31625695 DOI: 10.1002/adhm.201900708] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
149 Pinar E, Albarrán A, Baz JA, Mauri J. [Update on interventional cardiology]. Rev Esp Cardiol 2009;62 Suppl 1:101-16. [PMID: 19174054 DOI: 10.1016/s0300-8932(09)70045-4] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
150 Austin D, Oldroyd KG, Holmes DR Jr, Rihal CS, Galbraith PD, Ghali WA, Legrand V, Taeymans Y, McConnachie A, Pell JP; APPROACH Investigators., Belgian Working Group on Invasive Cardiology., Mayo Clinic PCI Registry., Scottish Coronary Revascularisation Registry. Drug-eluting stents: a study of international practice. Am Heart J 2009;158:576-84. [PMID: 19781417 DOI: 10.1016/j.ahj.2009.07.033] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
151 Banerjee S. The resolute™ integrity zotarolimus-eluting stent in coronary artery disease: a review. Cardiol Ther 2013;2:17-25. [PMID: 25135286 DOI: 10.1007/s40119-012-0010-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
152 Zou S, Xu Y. Association of the triglyceride-glucose index and major adverse cardiac and cerebrovascular events in female patients undergoing percutaneous coronary intervention with drug-eluting stents: A retrospective study. Diabetes Res Clin Pract 2021;181:109073. [PMID: 34592393 DOI: 10.1016/j.diabres.2021.109073] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
153 Kereiakes DJ. Medical and Catheter-Based Therapies for Managing Stable Coronary Disease: Lessons From the COURAGE Trial. Curr Treat Options Cardiovasc Med 2009;11:45-53. [PMID: 19141260 DOI: 10.1007/s11936-009-0005-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
154 Blich M, Shwiri TZ, Petcherski S, Osherov AB, Hammerman H. Clopidogrel Therapy Discontinuation Following Drug Eluting Stent Implantation in Real World Practice in Israel. Cardiol Res 2012;3:67-72. [PMID: 28348674 DOI: 10.4021/cr146w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
155 Kim J, Lee JM, Choi KH, Rhee TM, Hwang D, Park J, Ahn C, Park TK, Yang JH, Song YB, Choi JH, Hahn JY, Choi SH, Gwon HC. Differential Clinical Outcomes Between Angiographic Complete Versus Incomplete Coronary Revascularization, According to the Presence of Chronic Kidney Disease in the Drug-Eluting Stent Era. J Am Heart Assoc 2018;7:e007962. [PMID: 29449272 DOI: 10.1161/JAHA.117.007962] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
156 Hara M, Nishino M, Taniike M, Makino N, Kato H, Egami Y, Shutta R, Tanouchi J, Yamada Y. Serial angioscopic evaluation of neointimal coverage and incidence of thrombus formation after Paclitaxel-eluting stent implantation: comparison between 6- and 18-month follow-up. Clin Cardiol 2011;34:322-6. [PMID: 21432859 DOI: 10.1002/clc.20881] [Reference Citation Analysis]
157 Buchanan GL, Basavarajaiah S, Chieffo A. Stent thrombosis: incidence, predictors and new technologies. Thrombosis 2012;2012:956962. [PMID: 22577541 DOI: 10.1155/2012/956962] [Cited by in Crossref: 37] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
158 Vetrovec GW. SES for AMI: moving in the right direction. Catheter Cardiovasc Interv 2009;74:333-4. [PMID: 19642181 DOI: 10.1002/ccd.22185] [Reference Citation Analysis]
159 Kim DW, Her SH, Park HW, Chang K, Chung WS, Seung KB, Jeong MH, Kim HS, Gwon HC, Seong IW, Hwang KK, Chae SC, Kim KB, Kim YJ, Cha KS, Oh SK, Chae JK, Jung JH. Incremental age-related one-year MACCE after acute myocardial infarction in the drug-eluting stent era (from KAMIR-NIH registry). J Geriatr Cardiol 2018;15:574-84. [PMID: 30344541 DOI: 10.11909/j.issn.1671-5411.2018.09.005] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
160 Hyuk Im S, Hyeok Im D, Jeong Park S, Jung Y, Kim D, Hyun Kim S. Current status and future direction of metallic and polymeric materials for advanced vascular stents. Progress in Materials Science 2022. [DOI: 10.1016/j.pmatsci.2022.100922] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
161 Billinger M, Räber L, Hitz S, Stefanini GG, Pilgrim T, Stettler C, Zanchin T, Pulver C, Pfäffli N, Eberli F, Meier B, Kalesan B, Jüni P, Windecker S. Long-term clinical and angiographic outcomes of diabetic patients after revascularization with early generation drug-eluting stents. Am Heart J 2012;163:876-886.e2. [PMID: 22607867 DOI: 10.1016/j.ahj.2012.02.014] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
162 Sardella G, Briguori C, Garbo R, Romagnoli E, Pennacchi M, Donahue M, Boccuzzi G, Summaria F, Conti G, Canali E, Placentino F, Stio R, Lucisano L, Biondi-Zoccai G, Mancone M, Fedele F. Evidence from the Resorbable-polymer stent versus Unresorbable-polymer stent Deployment for coronary Intervention: (RUDI-2) registry. Int J Cardiol 2014;172:472-5. [PMID: 24461975 DOI: 10.1016/j.ijcard.2013.12.220] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
163 Jukema JW, Ahmed TA, Verschuren JJ, Quax PH. Restenosis after PCI. Part 2: prevention and therapy. Nat Rev Cardiol 2011;9:79-90. [PMID: 21989052 DOI: 10.1038/nrcardio.2011.148] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 4.5] [Reference Citation Analysis]
164 Colleran R, Kastrati A. Percutaneous coronary intervention: balloons, stents and scaffolds. Clin Res Cardiol 2018;107:55-63. [PMID: 30039189 DOI: 10.1007/s00392-018-1328-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
165 Maghzal GJ, Brennan SO, Homer VM, George PM. The molecular mechanisms of congenital hypofibrinogenaemia. Cell Mol Life Sci 2004;61:1427-38. [PMID: 15197468 DOI: 10.1007/s00018-004-3458-8] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 1.9] [Reference Citation Analysis]
166 Pessoa JA, Ferreira E, Araújo DV, Maia E, Silva FSMD, Oliveira MS, Albuquerque DC. Cost-effectiveness of Drug-Eluting Stents in Percutaneous Coronary Intervention in Brazil's Unified Public Health System (SUS). Arq Bras Cardiol 2020;115:80-9. [PMID: 32813829 DOI: 10.36660/abc.20180292] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
167 Rodríguez AE, Arismendi L, Romero G, Rodríguez-Granillo AM. Randomized trials of PCIs versus CABG surgery: why coronary stenting should remain the first choice of revascularization in non-diabetic patients and why the controversy is still present in diabetics. Expert Rev Cardiovasc Ther 2014;12:297-309. [PMID: 24490769 DOI: 10.1586/14779072.2014.882770] [Reference Citation Analysis]
168 Dobrolińska M, Gąsior P, Roleder T, Roleder-Dylewska M, Smolka G, Ochała A, Kedhi E, Wojakowski W. Short-term healing response after implantation of the thin-strut, fast-releasing sirolimus-eluting biodegradable polymer-coated Alex Plus stent: optical coherence tomography study. Postepy Kardiol Interwencyjnej 2020;16:187-91. [PMID: 32636904 DOI: 10.5114/aic.2020.96062] [Reference Citation Analysis]
169 Gao Z, Yang Y, Xu B, Chen J, Qiao S, Li J, Wu Y, Qin X, Yuan J, Gao R. Three year follow-up of the sirolimus-eluting stent and the paclitaxel-eluting stent in daily practice. Clin Cardiol 2009;32:E63-7. [PMID: 20014187 DOI: 10.1002/clc.20550] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
170 Pradhan A, Saran M, Vishwakarma P, Sethi R. Optical Coherence Tomography in In-Stent Restenosis: A Challenge Made Easier. Heart Views 2019;20:28-31. [PMID: 31143385 DOI: 10.4103/HEARTVIEWS.HEARTVIEWS_6_19] [Reference Citation Analysis]
171 Li M, Zhang J, Zhang Q, Pan J, Lu Z, Wei M. Coronary stent occlusion: reverse attenuation gradient sign observed at computed tomography angiography improves diagnostic performance. Eur Radiol 2015;25:568-74. [PMID: 25257855 DOI: 10.1007/s00330-014-3429-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
172 Stella SF, Gehling Bertoldi E, Polanczyk CA. Contemporary Context of Drug-Eluting Stents in Brazil: A Cost Utility Study. Med Decis Making 2016;36:1034-42. [PMID: 26964876 DOI: 10.1177/0272989X16636054] [Cited by in Crossref: 3] [Article Influence: 0.5] [Reference Citation Analysis]
173 Choi WG, Kim SH, Yoon HS, Lee EJ, Kim DW. Impact of an endothelial progenitor cell capturing stent on coronary microvascular function: comparison with drug-eluting stents. Korean J Intern Med 2015;30:42-8. [PMID: 25589834 DOI: 10.3904/kjim.2015.30.1.42] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
174 Vijakumaran U, Yazid MD, Hj Idrus RB, Abdul Rahman MR, Sulaiman N. Molecular Action of Hydroxytyrosol in Attenuation of Intimal Hyperplasia: A Scoping Review. Front Pharmacol 2021;12:663266. [PMID: 34093194 DOI: 10.3389/fphar.2021.663266] [Reference Citation Analysis]
175 Mecklai A, Bangalore S, Hochman J. How and when to decide on revascularization in stable ischemic heart disease. Curr Treat Options Cardiovasc Med 2013;15:79-92. [PMID: 23143818 DOI: 10.1007/s11936-012-0214-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
176 Liang S, Aiqun M, Jiwu L, Ping Z. TLR3 and TLR4 as potential clinical biomarkers for in-stent restenosis in drug-eluting stents patients. Immunol Res 2016;64:424-30. [PMID: 26318748 DOI: 10.1007/s12026-015-8685-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
177 Bowen PK, Shearier ER, Zhao S, Guillory RJ 2nd, Zhao F, Goldman J, Drelich JW. Biodegradable Metals for Cardiovascular Stents: from Clinical Concerns to Recent Zn-Alloys. Adv Healthc Mater 2016;5:1121-40. [PMID: 27094868 DOI: 10.1002/adhm.201501019] [Cited by in Crossref: 230] [Cited by in F6Publishing: 186] [Article Influence: 38.3] [Reference Citation Analysis]
178 Meng Y, Wang J, Sun J, Zhang F, Willis P, Li J, Wang H, Zhang T, Soriano S, Qiu B, Yang X. 3.0-T MR imaging of intracoronary local delivery of motexafin gadolinium into coronary artery walls. Radiology 2013;268:556-62. [PMID: 23513243 DOI: 10.1148/radiol.13121451] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
179 García-García HM, Garg S, Brugaletta S, Morocutti G, Ratner RE, Kolatkar NS, Kravitz BG, Miller DM, Huang C, Nesto RW, Serruys PW; APPROACH study group. Evaluation of in-stent restenosis in the APPROACH trial (Assessment on the Prevention of Progression by Rosiglitazone On Atherosclerosis in diabetes patients with Cardiovascular History). Int J Cardiovasc Imaging 2012;28:455-65. [PMID: 21359834 DOI: 10.1007/s10554-011-9836-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
180 Partida RA, Yeh RW. Contemporary Drug-Eluting Stent Platforms: Design, Safety, and Clinical Efficacy. Interv Cardiol Clin 2016;5:331-47. [PMID: 28582031 DOI: 10.1016/j.iccl.2016.02.003] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
181 Shafiq A, Gosch K, Amin AP, Ting HH, Spertus JA, Salisbury AC. Predictors and variability of drug-eluting vs bare-metal stent selection in contemporary percutaneous coronary intervention: Insights from the PRISM study. Clin Cardiol 2017;40:521-7. [PMID: 28300284 DOI: 10.1002/clc.22693] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
182 Fineschi M, D'Ascenzi F, Sirbu V, Mondillo S, Pierli C. Diagnosis and management of a patient with recurrent variant angina and history of percutaneous coronary intervention: vasospasm and percutaneous coronary intervention. J Cardiovasc Med (Hagerstown) 2018;19:31-3. [PMID: 29206694 DOI: 10.2459/JCM.0000000000000599] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
183 Cho JY, Ahn Y, Jeong MH. A bumpy and winding but right path to domestic drug-eluting coronary stents. Korean Circ J 2013;43:645-54. [PMID: 24255648 DOI: 10.4070/kcj.2013.43.10.645] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
184 Dai R, Liu Y, Zhou Y, Xiong X, Zhou W, Li W, Zhou W, Chen M. Potential of circulating pro-angiogenic microRNA expressions as biomarkers for rapid angiographic stenotic progression and restenosis risks in coronary artery disease patients underwent percutaneous coronary intervention. J Clin Lab Anal 2020;34:e23013. [PMID: 31495986 DOI: 10.1002/jcla.23013] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
185 Blair RW, Dunne NJ, Lennon AB, Menary GH. Multi-objective optimisation of material properties and strut geometry for poly(L-lactic acid) coronary stents using response surface methodology. PLoS One 2019;14:e0218768. [PMID: 31449528 DOI: 10.1371/journal.pone.0218768] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
186 Xhepa E, Tada T, Cassese S, King L, Ott I, Fusaro M, Kastrati A, Byrne RA. Safety and efficacy of the Yukon Choice Flex sirolimus-eluting coronary stent in an all-comers population cohort. Indian Heart J 2014;66:345-9. [PMID: 24973842 DOI: 10.1016/j.ihj.2014.05.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
187 Wandel S, Jüni P, Tendal B, Nüesch E, Villiger PM, Welton NJ, Reichenbach S, Trelle S. Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. BMJ. 2010;341:c4675. [PMID: 20847017 DOI: 10.1136/bmj.c4675] [Cited by in Crossref: 335] [Cited by in F6Publishing: 258] [Article Influence: 27.9] [Reference Citation Analysis]
188 Zahn R, Hamm CW, Zeymer U, Richardt G, Kelm M, Levenson B, Bonzel T, Tebbe U, Sabin G, Nienaber CA, Pfannebecker T, Senges J. Coronary stenting with the sirolimus-eluting stent in patients with restenosis after intracoronary brachytherapy: results from the prospective multicentre German Cypher Stent Registry. Clin Res Cardiol 2010;99:99-106. [PMID: 19882098 DOI: 10.1007/s00392-009-0088-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
189 LaBounty T, Sundaram B, Chetcuti S, Ruwende C, Kazerooni EA, Gurm HS. Stent size selection using 64-detector coronary computed tomography angiography: a comparison to invasive coronary angiography. Acad Radiol 2008;15:820-6. [PMID: 18572116 DOI: 10.1016/j.acra.2008.04.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
190 Legutko J, Zasada W, Kałuża GL, Heba G, Rzeszutko L, Jakala J, Dragan J, Klecha A, Giszterowicz D, Dobrowolski W. A clinical evaluation of the ProNOVA XR polymer-free sirolimus eluting coronary stent system in the treatment of patients with de novo coronary artery lesions (EURONOVA XR I study). Indian Heart J. 2013;65:388-394. [PMID: 23992999 DOI: 10.1016/j.ihj.2013.06.026] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
191 Canfield J, Totary-Jain H. 40 Years of Percutaneous Coronary Intervention: History and Future Directions. J Pers Med 2018;8:E33. [PMID: 30275411 DOI: 10.3390/jpm8040033] [Cited by in Crossref: 27] [Cited by in F6Publishing: 18] [Article Influence: 6.8] [Reference Citation Analysis]
192 Douglas PS, Brennan JM, Anstrom KJ, Sedrakyan A, Eisenstein EL, Haque G, Dai D, Kong DF, Hammill B, Curtis L, Matchar D, Brindis R, Peterson ED. Clinical effectiveness of coronary stents in elderly persons: results from 262,700 Medicare patients in the American College of Cardiology-National Cardiovascular Data Registry. J Am Coll Cardiol 2009;53:1629-41. [PMID: 19406337 DOI: 10.1016/j.jacc.2009.03.005] [Cited by in Crossref: 118] [Cited by in F6Publishing: 79] [Article Influence: 9.1] [Reference Citation Analysis]
193 Beohar N, Meyers SN, Erdogan A, Harinstein ME, Pieper K, Gagnon S, Davidson CJ. Off-label use of drug-eluting versus bare metal stents: a lesion-specific systematic review of long-term outcomes. J Interv Cardiol 2010;23:528-45. [PMID: 20735712 DOI: 10.1111/j.1540-8183.2010.00588.x] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
194 Fröhlich GM, Lansky AJ, Ko DT, Archangelidi O, De Palma R, Timmis A, Meier P. Drug eluting balloons for de novo coronary lesions - a systematic review and meta-analysis. BMC Med 2013;11:123. [PMID: 23657123 DOI: 10.1186/1741-7015-11-123] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
195 Saito S, Valdes-Chavarri M, Richardt G, Moreno R, Iniguez Romo A, Barbato E, Carrie D, Ando K, Merkely B, Kornowski R, Eltchaninoff H, James S, Wijns W; CENTURY II Investigators. A randomized, prospective, intercontinental evaluation of a bioresorbable polymer sirolimus-eluting coronary stent system: the CENTURY II (Clinical Evaluation of New Terumo Drug-Eluting Coronary Stent System in the Treatment of Patients with Coronary Artery Disease) trial. Eur Heart J 2014;35:2021-31. [PMID: 24847155 DOI: 10.1093/eurheartj/ehu210] [Cited by in Crossref: 122] [Cited by in F6Publishing: 83] [Article Influence: 15.3] [Reference Citation Analysis]
196 Yang G, Liu D, Liu RY, Xie M, Hoaglin DC. Efficient network meta-analysis: a confidence distribution approach. Stat Methodol 2014;20:105-25. [PMID: 25067933 DOI: 10.1016/j.stamet.2014.01.003] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 2.1] [Reference Citation Analysis]
197 Jámbor C, Spannagl M, Zwissler B. [Perioperative management of patients with coronary stents in non-cardiac surgery]. Anaesthesist 2009;58:971-85. [PMID: 19823781 DOI: 10.1007/s00101-009-1628-7] [Cited by in Crossref: 38] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
198 Head SJ, Hickey GL. Finding the forest through the trees in statistics: let the Statistical Primers in EJCTS/ICVTS guide you. Eur J Cardiothorac Surg 2018;53:697-9. [PMID: 29538747 DOI: 10.1093/ejcts/ezy010] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
199 Khaled W, de la Motte Rouge T, Amirault JC, Vignot S. [Non oncologic applications of molecular targeted therapies]. Bull Cancer 2012;99:953-62. [PMID: 23092598 DOI: 10.1684/bdc.2012.1641] [Reference Citation Analysis]
200 Widimský P. Resolute zotarolimus-eluting coronary stent system for the treatment of coronary artery disease. Expert Rev Med Devices 2014;11:247-57. [PMID: 24693989 DOI: 10.1586/17434440.2014.900434] [Reference Citation Analysis]
201 Yabe T, Toda M, Nakanishi R, Saito D, Watanabe I, Okubo R, Amano H, Ikeda T. Same or Different Drug-Eluting Stent Re-Implantation for Drug-Eluting Stent Restenosis: An Assessment Including Second-Generation Drug-Eluting Stents. J Interv Cardiol 2016;29:311-8. [PMID: 27245125 DOI: 10.1111/joic.12299] [Reference Citation Analysis]
202 Vandvik PO, Lincoff AM, Gore JM, Gutterman DD, Sonnenberg FA, Alonso-Coello P, Akl EA, Lansberg MG, Guyatt GH, Spencer FA. Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e637S-e668S. [PMID: 22315274 DOI: 10.1378/chest.11-2306] [Cited by in Crossref: 314] [Cited by in F6Publishing: 241] [Article Influence: 31.4] [Reference Citation Analysis]
203 Rocha-Singh KJ, Duval S, Jaff MR, Schneider PA, Ansel GM, Lyden SP, Mullin CM, Ioannidis JPA, Misra S, Tzafriri AR, Edelman ER, Granada JF, White CJ, Beckman JA; VIVA Physicians, Inc. Mortality and Paclitaxel-Coated Devices: An Individual Patient Data Meta-Analysis. Circulation 2020;141:1859-69. [PMID: 32370548 DOI: 10.1161/CIRCULATIONAHA.119.044697] [Cited by in Crossref: 62] [Cited by in F6Publishing: 17] [Article Influence: 31.0] [Reference Citation Analysis]
204 Zhou X, Ye Q, Zheng J, Kuang L, Zhu J, Yan H. IMP3 promotes re-endothelialization after arterial injury via increasing stability of VEGF mRNAhv. J Cell Mol Med 2022. [PMID: 35315195 DOI: 10.1111/jcmm.17225] [Reference Citation Analysis]
205 Lotfi A, Cui J, Wartak S, Columbo J, Mulvey S, Davis M, Schweiger M, Giugliano GR. Influence of low-dose aspirin (81 mg) on the incidence of definite stent thrombosis in patients receiving bare-metal and drug-eluting stents. Clin Cardiol 2011;34:567-71. [PMID: 21792981 DOI: 10.1002/clc.20938] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
206 Inoue T, Croce K, Morooka T, Sakuma M, Node K, Simon DI. Vascular inflammation and repair: implications for re-endothelialization, restenosis, and stent thrombosis. JACC Cardiovasc Interv 2011;4:1057-66. [PMID: 22017929 DOI: 10.1016/j.jcin.2011.05.025] [Cited by in Crossref: 270] [Cited by in F6Publishing: 250] [Article Influence: 27.0] [Reference Citation Analysis]
207 Ioannidis JP. Integration of evidence from multiple meta-analyses: a primer on umbrella reviews, treatment networks and multiple treatments meta-analyses. CMAJ 2009;181:488-93. [PMID: 19654195 DOI: 10.1503/cmaj.081086] [Cited by in Crossref: 259] [Cited by in F6Publishing: 248] [Article Influence: 19.9] [Reference Citation Analysis]
208 Yao HM, Wan YD, Zhang XJ, Shen DL, Zhang JY, Li L, Zhao LS, Sun TW. Long-term follow-up results in patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stents: results from a single high-volume PCI centre. BMJ Open 2014;4:e004892. [PMID: 25113554 DOI: 10.1136/bmjopen-2014-004892] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
209 Malik AH, Gupta R, Chakraborty S, Mahajan P, Bandyopadhyay D, Yandrapalli S, Zaid S, Sreenivasan J, Chaturvedi A, Mehta SS, Vyas AV, Patel NC, Combs WG, Ahmad H. Effect of genotype guided oral P2Y12 inhibitor selection after percutaneous coronary intervention: A systematic review and meta-analysis of randomized clinical trials. Cardiovascular Revascularization Medicine 2022. [DOI: 10.1016/j.carrev.2022.01.005] [Reference Citation Analysis]
210 Ko T, Yang CH, Mao CT, Kuo LT, Hsieh MJ, Chen DY, Wang CY, Lin YS, Hsieh IC, Chen SW, Hung MJ, Cherng WJ, Chen TH. Effects of National Hospital Accreditation in Acute Coronary Syndrome on In-Hospital Mortality and Clinical Outcomes. Acta Cardiol Sin 2020;36:416-27. [PMID: 32952351 DOI: 10.6515/ACS.202009_36(5).20200421A] [Reference Citation Analysis]
211 Han B, Ge CQ, Zhang HG, Zhou CG, Ji GH, Yang Z, Zhang L. Effects of tripterygium glycosides on restenosis following endovascular treatment. Mol Med Rep 2016;13:4959-68. [PMID: 27108914 DOI: 10.3892/mmr.2016.5149] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
212 Gibbons RD, Amatya AK, Brown CH, Hur K, Marcus SM, Bhaumik DK, Mann JJ. Post-approval drug safety surveillance. Annu Rev Public Health 2010;31:419-37. [PMID: 20070192 DOI: 10.1146/annurev.publhealth.012809.103649] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 2.9] [Reference Citation Analysis]
213 Lemesle G, Delhaye C. [Decreasing incidence of stent thrombosis]. Ann Cardiol Angeiol (Paris) 2011;60:338-46. [PMID: 22054519 DOI: 10.1016/j.ancard.2011.09.001] [Reference Citation Analysis]
214 Giordano A, Polimeno M, Corcione N, Fattore L, Di Lorenzo L, Biondi-Zoccai G, Ferraro P, Romano MF. Synergy between direct coronary stenting technique and use of the novel thin strut cobalt chromium Skylor™ stent: the MACE in follow up patients treated with Skylor stent [MILES Study]. Curr Cardiol Rev 2012;8:6-13. [PMID: 22845811 DOI: 10.2174/157340312801215818] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
215 Davierwala PM, Mohr FW. Surgical versus percutaneous revascularization in patients with multivessel coronary artery disease. Curr Atheroscler Rep 2014;16:461. [PMID: 25344743 DOI: 10.1007/s11883-014-0461-x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
216 Lee DH, de la Torre Hernandez JM. The Newest Generation of Drug-eluting Stents and Beyond. Eur Cardiol 2018;13:54-9. [PMID: 30310472 DOI: 10.15420/ecr.2018:8:2] [Cited by in Crossref: 49] [Cited by in F6Publishing: 29] [Article Influence: 12.3] [Reference Citation Analysis]
217 Xue H, Luo Z, Brown T, Beier S. Design of Self-Expanding Auxetic Stents Using Topology Optimization. Front Bioeng Biotechnol 2020;8:736. [PMID: 32766219 DOI: 10.3389/fbioe.2020.00736] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
218 Ferenc M, Gick M, Kienzle RP, Bestehorn HP, Werner KD, Comberg T, Zhao M, Buettner HJ, Neumann FJ. Long-term outcome of percutaneous catheter intervention for de novo coronary bifurcation lesions with drug-eluting stents or bare-metal stents. Am Heart J 2010;159:454-61. [PMID: 20211309 DOI: 10.1016/j.ahj.2009.11.032] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
219 Paramasivam G, Devasia T, Jayaram A, U K AR, Rao MS, Vijayvergiya R, Nayak K. In-stent restenosis of drug-eluting stents in patients with diabetes mellitus: Clinical presentation, angiographic features, and outcomes. Anatol J Cardiol 2020;23:28-34. [PMID: 31911567 DOI: 10.14744/AnatolJCardiol.2019.72916] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
220 Mølstad P, Nordrehaug JE, Steigen T, Giil LM, Wilsgaard T, Wiseth R, Bønaa KH. The Effect of Drug-Eluting Stents on Target Lesion Revascularization in Native Coronary Arteries: Results from the NORSTENT Randomized Study. Cardiology 2020;145:333-41. [PMID: 32097932 DOI: 10.1159/000506042] [Reference Citation Analysis]
221 Gray WA, Jaff MR, Parikh SA, Ansel GM, Brodmann M, Krishnan P, Razavi MK, Vermassen F, Zeller T, White R, Ouriel K, Adelman MA, Lyden SP. Mortality Assessment of Paclitaxel-Coated Balloons: Patient-Level Meta-Analysis of the ILLUMENATE Clinical Program at 3 Years. Circulation 2019;140:1145-55. [PMID: 31567024 DOI: 10.1161/CIRCULATIONAHA.119.040518] [Cited by in Crossref: 35] [Cited by in F6Publishing: 10] [Article Influence: 11.7] [Reference Citation Analysis]
222 Généreux P, Mehran R. Are drug-eluting stents safe in the long term? CMAJ 2009;180:154-5. [PMID: 19106153 DOI: 10.1503/cmaj.081907] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
223 Testa L, Biondi Zoccai G, Tomai F, Ribichini F, Indolfi C, Tamburino C, Bartorelli A, Petronio AS, Bedogni F, De Carlo M. Italian Diffuse/Multivessel Disease ABSORB Prospective Registry (IT-DISAPPEARS). Study design and rationale. J Cardiovasc Med (Hagerstown) 2015;16:253-8. [PMID: 25469734 DOI: 10.2459/JCM.0000000000000219] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.9] [Reference Citation Analysis]
224 Yabe T, Toda M, Nakanishi R, Saito D, Watanabe I, Okubo R, Amano H, Ikeda T. Clinical outcome of treatment with or without a final kissing balloon technique for bifurcation in-stent restenosis lesions. J Cardiol 2017;69:808-14. [PMID: 27692566 DOI: 10.1016/j.jjcc.2016.08.014] [Reference Citation Analysis]
225 Fawzy AY, Kenawi MM, Aziz AAE, Moharam AN, Attia IM. Comparison between the Outcomes of Using Biodegradable-Polymer Drug-Eluting Stents and Those of Using Durable-Polymer Drug-Eluting Stents in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention. Open Access Maced J Med Sci 2019;7:1466-70. [PMID: 31198456 DOI: 10.3889/oamjms.2019.345] [Reference Citation Analysis]
226 Leschke M, Nhan VT, Waliszewski M, Palacios V, Horváth I, Ivanov VA, Tresukosol D, Avraamides P, Schneider A, Unverdorben M. The 'all comer' Coroflex Please drug-eluting stent registry in Europe and Asia - an overall and transcontinental assessment of the 10-month major adverse cardiac events. Indian Heart J 2012;64:453-61. [PMID: 23102382 DOI: 10.1016/j.ihj.2012.08.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
227 Hu S, Zhu Y, Zhang Y, Dai J, Li L, Dauerman H, Soeda T, Wang Z, Lee H, Wang C, Zhe C, Wang Y, Zheng G, Zhang S, Jia H, Yu B, Jang IK. Management and Outcome of Patients With Acute Coronary Syndrome Caused by Plaque Rupture Versus Plaque Erosion: An Intravascular Optical Coherence Tomography Study. J Am Heart Assoc 2017;6:e004730. [PMID: 28235809 DOI: 10.1161/JAHA.116.004730] [Cited by in Crossref: 21] [Cited by in F6Publishing: 8] [Article Influence: 4.2] [Reference Citation Analysis]
228 Coeugniet E, Harris PG, Soulez G, Paek LS, Dellifraine P, Danino MA. [Interventional angioradiology as a solution for microsurgical flap failure]. Ann Chir Plast Esthet 2013;58:188-93. [PMID: 23602272 DOI: 10.1016/j.anplas.2013.02.001] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
229 Alfirevic Z, Keeney E, Dowswell T, Welton NJ, Dias S, Jones LV, Navaratnam K, Caldwell DM. Labour induction with prostaglandins: a systematic review and network meta-analysis. BMJ 2015;350:h217. [PMID: 25656228 DOI: 10.1136/bmj.h217] [Cited by in Crossref: 66] [Cited by in F6Publishing: 51] [Article Influence: 9.4] [Reference Citation Analysis]
230 Verma B, Patel A, Katyal D, Singh VR, Singh AK, Singh A, Kumar M, Nagarkoti P. Real World Experience of a Biodegradable Polymer Sirolimus-Eluting Stent (Yukon Choice PC Elite) in Patients with Acute ST-Segment Elevation Myocardial Infarction Undergoing Primary Angioplasty: A Multicentric Observational Study (The Elite India Study). Open Access Maced J Med Sci 2019;7:1103-9. [PMID: 31049089 DOI: 10.3889/oamjms.2019.241] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
231 Behr T, Kuch B, Behr W, von Scheidt W. Optimizing of thienopyridine therapy by multiple electrode platelet aggregometry in clopidogrel low responders undergoing PCI. Clin Res Cardiol 2011;100:907-14. [PMID: 21533581 DOI: 10.1007/s00392-011-0321-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
232 Panchal K, Patel S, Bhatt P. Drug-eluting stents in multivessel coronary artery disease: cost effectiveness and clinical outcomes. Adv Pharmacol Sci 2012;2012:679013. [PMID: 23346105 DOI: 10.1155/2012/679013] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
233 Kobo O, Saada M, Meisel SR, Hellou E, Frimerman A, Fanne RA, Mohsen J, Danon A, Roguin A. Modern Stents: Where Are We Going? Rambam Maimonides Med J 2020;11. [PMID: 32374258 DOI: 10.5041/RMMJ.10403] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
234 Hsieh CF, Huang WF, Chiang YT, Chen CY. Effects of Clopidogrel and Proton Pump Inhibitors on Cardiovascular Events in Patients with Type 2 Diabetes Mellitus after Drug-Eluting Stent Implantation: A Nationwide Cohort Study. PLoS One 2015;10:e0135915. [PMID: 26313000 DOI: 10.1371/journal.pone.0135915] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
235 Fuster V. [From complex multivessel disease to cardiovascular health]. Rev Esp Cardiol 2010;63 Suppl 2:3-11. [PMID: 20540896 DOI: 10.1016/s0300-8932(10)70148-2] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
236 Lee CH, Choi SW, Jun SW, Hwang J, Kim IC, Cho YK, Park HS, Yoon HJ, Kim H, Nam CW, Han S, Kim KB, Hur SH. Clinical impact of diabetes mellitus on 2-year clinical outcomes following PCI with second-generation drug-eluting stents; Landmark analysis findings from patient registry: Pooled analysis of the Korean multicenter drug-eluting stent registry. PLoS One 2020;15:e0234362. [PMID: 32520973 DOI: 10.1371/journal.pone.0234362] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
237 Feinberg J, Nielsen EE, Greenhalgh J, Hounsome J, Sethi NJ, Safi S, Gluud C, Jakobsen JC. Drug-eluting stents versus bare-metal stents for acute coronary syndrome. Cochrane Database Syst Rev 2017;8:CD012481. [PMID: 28832903 DOI: 10.1002/14651858.CD012481.pub2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
238 Li L, Wang R, Shi HH, Xie L, Li JD, Kong WC, Tang JT, Ke DN, Zhao LY. In vitro study on the feasibility of magnetic stent hyperthermia for the treatment of cardiovascular restenosis. Exp Ther Med 2013;6:347-54. [PMID: 24137187 DOI: 10.3892/etm.2013.1177] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
239 Wu JJ, Way JAH, Roy P, Yong A, Lowe H, Kritharides L, Brieger D. Biodegradable polymer versus second-generation durable polymer drug-eluting stents in patients with coronary artery disease: A meta-analysis. Health Sci Rep 2018;1:e93. [PMID: 30623046 DOI: 10.1002/hsr2.93] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
240 Marchini JF, Gomes WF, Moulin B, Perin MA, Oliveira LA, Arruda JA, Lima VC, Lima AA, Caramori PR, Medeiros CR, Barbosa MR, Brito FS Jr, Ribeiro EE, Lemos PA. Very late outcomes of drug-eluting stents coated with biodegradable polymers: insights from the 5-year follow-up of the randomized PAINT trial. Cardiovasc Diagn Ther 2014;4:480-6. [PMID: 25610805 DOI: 10.3978/j.issn.2223-3652.2014.12.05] [Reference Citation Analysis]
241 Bauer T, Nienaber CA, Akin I, Kuck KH, Hochadel M, Senges J, Fetsch T, Tebbe U, Willich SN, Stumpf J, Sabin GV, Silber S, Richardt G, Zahn R; DES.DE Study Group. Comparison between on-label versus off-label use of drug-eluting coronary stents in clinical practice: results from the German DES.DE-Registry. Clin Res Cardiol 2011;100:701-9. [PMID: 21416192 DOI: 10.1007/s00392-011-0301-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
242 Seidlitz A, Wentzlaff M, Weitschies W. Controlling drug delivery from coronary stents: are we aiming for the right targets? Ther Deliv 2015;6:705-20. [PMID: 26149786 DOI: 10.4155/tde.15.25] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
243 Tang Z, Gu J, Sun P, Zhao J, Zhao Y. Identification of functional modules induced by bare-metal stents and paclitaxel-eluting stents in coronary heart disease. Exp Ther Med 2018;15:3801-8. [PMID: 29556263 DOI: 10.3892/etm.2018.5879] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
244 Akin I, Schneider H, Ince H, Kische S, Rehders TC, Chatterjee T, Nienaber CA. Second- and third-generation drug-eluting coronary stents: progress and safety. Herz 2011;36:190-6. [PMID: 21505934 DOI: 10.1007/s00059-011-3458-z] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 3.0] [Reference Citation Analysis]
245 Ailianou A, Ramachandran K, Kossuth MB, Oberhauser JP, Kornfield JA. Multiplicity of morphologies in poly (l-lactide) bioresorbable vascular scaffolds. Proc Natl Acad Sci U S A 2016;113:11670-5. [PMID: 27671659 DOI: 10.1073/pnas.1602311113] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
246 Jang S, Jeong MH, Lim KS, Bae IH, Park JK, Park DS, Shim JW, Kim JH, Kim HK, Sim DS, Hong YJ, Ahn Y, Kang JC. Effect of Stents Coated with Artemisinin or Dihydroartemisinin in a Porcine Coronary Restenosis Model. Korean Circ J 2017;47:115-22. [PMID: 28154599 DOI: 10.4070/kcj.2016.0278] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
247 Bil J, Gil RJ. Bioresorbable vascular scaffolds-what does the future bring? J Thorac Dis 2016;8:E741-5. [PMID: 27619478 DOI: 10.21037/jtd.2016.05.80] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
248 Panaich S, Schreiber T, Grines C. Bioresorbable Scaffolds. Interv Cardiol 2014;9:175-9. [PMID: 29588798 DOI: 10.15420/icr.2014.9.3.175] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
249 Zhu J, Zhang Q, Chen L, Zhang C, Zhou X, Yuan Y, Zhang R. Three-Year Clinical Outcomes of a Polymer-Free Paclitaxel-Eluting Microporous Stent in Real-World Practice: Final Results of the Safety and Efficacy Registry of the Yinyi Stent (SERY-I). Acta Cardiol Sin 2017;33:28-33. [PMID: 28115804 DOI: 10.6515/acs20160131b] [Reference Citation Analysis]
250 Shenoy C, Boura J, Orshaw P, Harjai KJ. Drug-eluting stents in patients with chronic kidney disease: a prospective registry study. PLoS One 2010;5:e15070. [PMID: 21124771 DOI: 10.1371/journal.pone.0015070] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
251 Ortolani P, Solinas E, Guastaroba P, Casella G, Manari A, Piovaccari G, Balducelli M, Tondi S, Percoco G, Tarantino F, Passerini F, Rossi R, Vignali L, De Palma R, Grilli R, Marzocchi A. Long-term clinical outcomes after drug eluting stent implantation in women with de novo coronary lesions. Results from the REAL (REgistro Regionale AngiopLastiche Emilia-Romagna) multicenter registry. Int J Cardiol 2011;149:55-62. [PMID: 20060183 DOI: 10.1016/j.ijcard.2009.11.044] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
252 Neyt M, De Laet C, De Ridder A, Van Brabandt H. Cost effectiveness of drug-eluting stents in Belgian practice: healthcare payer perspective. Pharmacoeconomics 2009;27:313-27. [PMID: 19485427 DOI: 10.2165/00019053-200927040-00004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
253 Abu Sharar H, Gomes B, Chorianopoulos E, Kaya Z, Gleissner CA, Katus HA, Bekeredjian R. Procedural advantages of a novel coronary stent design with ultra-thin struts and bioabsorbable abluminal polymer coating in an all-comers registry. Postepy Kardiol Interwencyjnej 2018;14:240-6. [PMID: 30302099 DOI: 10.5114/aic.2018.78326] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
254 Bahnson ES, Kassam HA, Moyer TJ, Jiang W, Morgan CE, Vercammen JM, Jiang Q, Flynn ME, Stupp SI, Kibbe MR. Targeted Nitric Oxide Delivery by Supramolecular Nanofibers for the Prevention of Restenosis After Arterial Injury. Antioxid Redox Signal 2016;24:401-18. [PMID: 26593400 DOI: 10.1089/ars.2015.6363] [Cited by in Crossref: 45] [Cited by in F6Publishing: 35] [Article Influence: 7.5] [Reference Citation Analysis]
255 Mauri L, Silbaugh TS, Wolf RE, Zelevinsky K, Lovett A, Zhou Z, Resnic FS, Normand SL. Long-term clinical outcomes after drug-eluting and bare-metal stenting in Massachusetts. Circulation 2008;118:1817-27. [PMID: 18852368 DOI: 10.1161/CIRCULATIONAHA.108.781377] [Cited by in Crossref: 113] [Cited by in F6Publishing: 27] [Article Influence: 8.1] [Reference Citation Analysis]
256 Wykrzykowska JJ, Warnholtz A, de Jaeger P, Curzen N, Oldroyd KG, Collet JP, Ten Berg JM, Rademaker T, Goedhart D, Lissens J, Kint PP, Serruys PW. Effect of clopidogrel discontinuation at 1 year after drug eluting stent placement on soluble CD40L, P-selectin and C-reactive protein levels: DECADES (Discontinuation Effect of Clopidogrel After Drug Eluting Stent): a multicenter, open-label study. J Thromb Thrombolysis 2009;28:410-7. [PMID: 19504052 DOI: 10.1007/s11239-009-0354-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
257 Hammett CJ, Stewart PJ, Atherton JJ. The fall and rise of drug-eluting stents. Med J Aust 2011;195:110-1. [PMID: 21806525 DOI: 10.5694/j.1326-5377.2011.tb03234.x] [Reference Citation Analysis]
258 Hammoudeh AJ, Tabbalat R, Alhaddad IA, Khader Y, Jarrah M, Izraiq M, Al-Mousa E. Short- and long-term outcomes in Middle Eastern diabetic patients after percutaneous coronary intervention: results from The First Jordanian PCI Registry (JoPCR1). Diabetol Int 2017;8:30-8. [PMID: 30603304 DOI: 10.1007/s13340-016-0273-z] [Cited by in Crossref: 4] [Article Influence: 0.7] [Reference Citation Analysis]
259 Nakazawa G, Otsuka F, Nakano M, Vorpahl M, Yazdani SK, Ladich E, Kolodgie FD, Finn AV, Virmani R. The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. J Am Coll Cardiol. 2011;57:1314-1322. [PMID: 21376502 DOI: 10.1016/j.jacc.2011.01.011] [Cited by in Crossref: 646] [Cited by in F6Publishing: 470] [Article Influence: 58.7] [Reference Citation Analysis]
260 Alghrairi M, Sulaiman N, Mutashar S. Health Care Monitoring and Treatment for Coronary Artery Diseases: Challenges and Issues. Sensors (Basel) 2020;20:E4303. [PMID: 32752231 DOI: 10.3390/s20154303] [Reference Citation Analysis]
261 Echeverri D, Móntes F, Delgadillo A, Cabrales J. Effects of the simultaneous use of drug-eluting stents and statins in an atherosclerotic animal model. Clin Investig Arterioscler 2013;25:16-24. [PMID: 23522277 DOI: 10.1016/j.arteri.2012.10.004] [Reference Citation Analysis]
262 Cho MS, Park DW. Stent thrombosis and optimal duration of dual antiplatelet therapy after coronary stenting in contemporary practice. Korean J Intern Med 2017;32:769-79. [PMID: 28823143 DOI: 10.3904/kjim.2016.391] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
263 Buccheri D, Piraino D, Andolina G, Cortese B. Understanding and managing in-stent restenosis: a review of clinical data, from pathogenesis to treatment. J Thorac Dis 2016;8:E1150-62. [PMID: 27867580 DOI: 10.21037/jtd.2016.10.93] [Cited by in Crossref: 109] [Cited by in F6Publishing: 78] [Article Influence: 18.2] [Reference Citation Analysis]
264 Spitzer E, Windecker S. Paclitaxel-eluting stents in ST-segment elevation myocardial infarction. Rev Esp Cardiol (Engl Ed) 2014;67:974-9. [PMID: 25444381 DOI: 10.1016/j.rec.2014.07.011] [Reference Citation Analysis]
265 Sharma PK, Chhatriwalla AK, Cohen DJ, Jang JS, Baweja P, Gosch K, Jones P, Bach RG, Arnold SV, Spertus JA. Predicting long-term bleeding after percutaneous coronary intervention. Catheter Cardiovasc Interv 2017;89:199-206. [PMID: 27037854 DOI: 10.1002/ccd.26529] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
266 Ramos GC. Relevant aspects of coronary artery disease in candidates for non-cardiac surgery. Rev Bras Anestesiol 2010;60:659-65, 366-9. [PMID: 21146063 DOI: 10.1016/S0034-7094(10)70082-9] [Reference Citation Analysis]
267 Dzavík V, Buller CE, Devlin G, Carere RG, Mancini GB, Cantor WJ, Buszman PE, Rankin JM, Vozzi C, Ross JR, Forman S, Barton BA, Lamas AG, Hochman JS. Angiographic and clinical outcomes of drug-eluting versus bare metal stent deployment in the Occluded Artery Trial. Catheter Cardiovasc Interv 2009;73:771-9. [PMID: 19309733 DOI: 10.1002/ccd.21930] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
268 Alfonso F, Coughlan JJ, Giacoppo D, Kastrati A, Byrne RA. Management of in-stent restenosis. EuroIntervention 2022;18:e103-23. [PMID: 35656726 DOI: 10.4244/EIJ-D-21-01034] [Reference Citation Analysis]
269 Bates ER, Menees DS. My stent is better than your stent...Or is it? JACC Cardiovasc Interv 2011;4:551-3. [PMID: 21596328 DOI: 10.1016/j.jcin.2011.02.006] [Reference Citation Analysis]
270 Sun A, Wang Z, Zhan F, Xu Z, Deng X. A NEW WAY TO OPTIMIZE DRUG RELEASE RATE OF DRUG ELUTING STENT (DES). J Mech Med Biol 2015;15:1550064. [DOI: 10.1142/s0219519415500645] [Reference Citation Analysis]
271 Atallah AN. Primum non nocere. Quomo sapere?. Firstly, do no harm. How can we know this? Drug-eluting stents versus surgery. Sao Paulo Med J 2008;126:143-4. [PMID: 18711651 DOI: 10.1590/s1516-31802008000300001] [Reference Citation Analysis]
272 Garg S, Serruys PW. An update on drug-eluting stents. Curr Treat Options Cardiovasc Med 2013;15:61-78. [PMID: 23192748 DOI: 10.1007/s11936-012-0219-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
273 Kerkmeijer LS, Farhan S, Mehran R, Dangas GD. Diabetes mellitus and multivessel coronary artery disease: an ongoing battle for an ideal treatment strategy. Ann Transl Med 2017;5:261. [PMID: 28706929 DOI: 10.21037/atm.2017.03.92] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
274 Lai CL, Wu CF, Kuo RN, Yang YY, Chen MF, Chan KA, Lai MS. Clinical outcomes in low risk coronary artery disease patients treated with different limus-based drug-eluting stents--a nationwide retrospective cohort study using insurance claims database. PLoS One 2015;10:e0122860. [PMID: 25848942 DOI: 10.1371/journal.pone.0122860] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
275 Kibret T, Richer D, Beyene J. Bias in identification of the best treatment in a Bayesian network meta-analysis for binary outcome: a simulation study. Clin Epidemiol 2014;6:451-60. [PMID: 25506247 DOI: 10.2147/CLEP.S69660] [Cited by in Crossref: 5] [Cited by in F6Publishing: 15] [Article Influence: 0.6] [Reference Citation Analysis]
276 Fagel ND, van Nooijen FC, Maarse M, Slagboom T, Herrman JP, van der Schaaf RJ, Amoroso G, Patterson MS, Laarman GJ, Suttorp MJ, Vink MA. Five-year results of the complete versus culprit vessel percutaneous coronary intervention in multivessel disease using drug-eluting stents II (CORRECT II) study: a prospective, randomised controlled trial. Neth Heart J 2019;27:310-20. [PMID: 30868547 DOI: 10.1007/s12471-019-1252-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
277 Schwalm JD, Ahmad M, Velianou JL, Pericak D, Natarajan MK. Long-term outcomes with paclitaxel-eluting stents versus bare metal stents in everyday practice: a Canadian experience. Can J Cardiol 2010;26:e40-4. [PMID: 20151057 DOI: 10.1016/s0828-282x(10)70005-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
278 Zhang X, Xie J, Li G, Chen Q, Xu B. Head-to-head comparison of sirolimus-eluting stents versus paclitaxel-eluting stents in patients undergoing percutaneous coronary intervention: a meta-analysis of 76 studies. PLoS One 2014;9:e97934. [PMID: 24844284 DOI: 10.1371/journal.pone.0097934] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
279 Mulukutla SR, Vlachos HA, Marroquin OC, Selzer F, Holper EM, Abbott JD, Laskey WK, Williams DO, Smith C, Anderson WD, Lee JS, Srinivas V, Kelsey SF, Kip KE. Impact of drug-eluting stents among insulin-treated diabetic patients: a report from the National Heart, Lung, and Blood Institute Dynamic Registry. JACC Cardiovasc Interv 2008;1:139-47. [PMID: 19212456 DOI: 10.1016/j.jcin.2008.02.005] [Cited by in Crossref: 39] [Cited by in F6Publishing: 30] [Article Influence: 3.0] [Reference Citation Analysis]
280 Moreno R. ¿El infarto agudo de miocardio es un escenario adecuado para los stents farmacoactivos? Revista Española de Cardiología 2008;61:346-8. [DOI: 10.1157/13117725] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
281 Shah SR, Fatima M, Dharani AM, Shahnawaz W, Shah SA. Bioresorbable vascular scaffold versus metallic stent in percutaneous coronary intervention: results of the AIDA trial. J Community Hosp Intern Med Perspect 2017;7:307-8. [PMID: 29147473 DOI: 10.1080/20009666.2017.1374111] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
282 Zhang H, Wang X, Deng W, Wang S, Ge J, Toft E. Randomized clinical trial comparing abluminal biodegradable polymer sirolimus-eluting stents with durable polymer sirolimus-eluting stents: Nine months angiographic and 5-year clinical outcomes. Medicine (Baltimore) 2016;95:e4820. [PMID: 27661023 DOI: 10.1097/MD.0000000000004820] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
283 Jeżewski MP, Kubisa MJ, Eyileten C, De Rosa S, Christ G, Lesiak M, Indolfi C, Toma A, Siller-Matula JM, Postuła M. Bioresorbable Vascular Scaffolds-Dead End or Still a Rough Diamond? J Clin Med 2019;8:E2167. [PMID: 31817876 DOI: 10.3390/jcm8122167] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
284 Her AY, Shin ES. Current Management of In-Stent Restenosis. Korean Circ J. 2018;48:337-349. [PMID: 29737639 DOI: 10.4070/kcj.2018.0103] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.8] [Reference Citation Analysis]
285 Kaul U, Bhatia V. Choice of DES: is there a difference? Heart Asia 2009;1:11-5. [PMID: 27325919 DOI: 10.1136/ha.2008.000224] [Reference Citation Analysis]
286 Chaturvedula S, Diver D, Vashist A. Antiplatelet Therapy in Coronary Artery Disease: A Daunting Dilemma. J Clin Med 2018;7:E74. [PMID: 29642547 DOI: 10.3390/jcm7040074] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
287 Belland BR, Walker AE, Kim NJ. A Bayesian Network Meta-Analysis to Synthesize the Influence of Contexts of Scaffolding Use on Cognitive Outcomes in STEM Education. Rev Educ Res 2017;87:1042-81. [PMID: 29200508 DOI: 10.3102/0034654317723009] [Cited by in Crossref: 17] [Article Influence: 3.4] [Reference Citation Analysis]
288 El-Said HG, Ebrahim M, Moore JW. Left main coronary artery stenting in a 3.6 kg infant after arterial switch operation for transposition of the great arteries. Ann Pediatr Cardiol 2015;8:143-6. [PMID: 26085768 DOI: 10.4103/0974-2069.157033] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
289 Pfisterer M, Bertel O, Bonetti PO, Brunner-La Rocca HP, Eberli FR, Erne P, Galatius S, Hornig B, Kiowski W, Pachinger O, Pedrazzini G, Rickli H, De Servi S, Kaiser C; BASKET-PROVE Investigators. Drug-eluting or bare-metal stents for large coronary vessel stenting? The BASKET-PROVE (PROspective Validation Examination) trial: study protocol and design. Am Heart J 2008;155:609-14. [PMID: 18371466 DOI: 10.1016/j.ahj.2007.11.011] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
290 He M, Gong Y, Shi J, Pan Z, Zou H, Sun D, Tu X, Tan X, Li J, Li W, Liu B, Xue J, Sheng L, Xiu C, Yang N, Xue H, Ding X, Yu C, Li Y. Plasma microRNAs as potential noninvasive biomarkers for in-stent restenosis. PLoS One 2014;9:e112043. [PMID: 25427155 DOI: 10.1371/journal.pone.0112043] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 3.8] [Reference Citation Analysis]
291 Rao C, Bongiovanni T, Li X, Gao H, Zhang H, Li J, Zhao Y, Yuan X, Hua K, Hu S, Krumholz HM, Jiang L, Zheng Z; China PEACE Collaborative Group. The China Patient-Centred Evaluative Assessment of Cardiac Events (China PEACE)-Prospective Study of 3-Vessel Disease: rationale and design. BMJ Open 2016;6:e009743. [PMID: 26880670 DOI: 10.1136/bmjopen-2015-009743] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
292 Mont E, Cresswell N, Burke A. Pathologic findings of coronary stents: a comparison of sudden coronary death versus non-cardiac death. J Forensic Sci 2013;58:1542-8. [PMID: 24164207 DOI: 10.1111/1556-4029.12285] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
293 Kang M, Jeong CW, Kwak C, Kim HH, Ku JH. Single, immediate postoperative instillation of chemotherapy in non-muscle invasive bladder cancer: a systematic review and network meta-analysis of randomized clinical trials using different drugs. Oncotarget 2016;7:45479-88. [PMID: 27323781 DOI: 10.18632/oncotarget.9991] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
294 Alkhalil M, Conlon CP, Ashrafian H, Choudhury RP. Aggressive restenosis after percutaneous intervention in two coronary loci in a patient with human immunodeficiency virus infection. World J Clin Cases 2017; 5(2): 40-45 [PMID: 28255546 DOI: 10.12998/wjcc.v5.i2.40] [Reference Citation Analysis]
295 Shim JW, Kim SS, Kim HK, Bae IH, Park DS, Park JK, Kim JU, Kim HB, Lee MY, Kim JS, Kim JH, Koo BS, Jeong KJ, Kim SU, Kim MC, Sim DS, Hong YJ, Ahn Y, Lim KS, Jeong MH. Effect of Novel Polymer-Free Nitrogen-Doped Titanium Dioxide Film-Coated Coronary Stent Loaded With Mycophenolic Acid. Front Bioeng Biotechnol 2021;9:650408. [PMID: 34778222 DOI: 10.3389/fbioe.2021.650408] [Reference Citation Analysis]
296 Gomez-Lara J, Heo JH, Brugaletta S, Garg S, Garcia-Garcia HM, van Geuns RJ, Silber S, Windecker S, Serruys PW. Risk of target lesion failure in relationship to vessel angiographic geometry and stent conformability using the second generation of drug-eluting stents. Am Heart J 2011;162:1069-1079.e2. [PMID: 22137081 DOI: 10.1016/j.ahj.2011.09.010] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
297 Tabaczewski P, Nadesan S, Lim SH. Early renal arterial stent thrombosis associated with the JAK2 V617F mutation. Leuk Res 2009;33:573-4. [PMID: 18639337 DOI: 10.1016/j.leukres.2008.06.016] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
298 Feinberg MW. Healing the injured vessel wall using microRNA-facilitated gene delivery. J Clin Invest 2014;124:3694-7. [PMID: 25133421 DOI: 10.1172/JCI77509] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
299 Oh PC, Suh SY, Kang WC, Lee K, Han SH, Ahn T, Shin EK. The efficacy and safety of drug-eluting balloons for the treatment of in-stent restenosis as compared with drug-eluting stents and with conventional balloon angioplasty. Korean J Intern Med 2016;31:501-6. [PMID: 26951915 DOI: 10.3904/kjim.2014.189] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
300 Eshtehardi P, Windecker S, Cook S, Billinger M, Togni M, Garachemani A, Meier B, Hess OM, Wenaweser P. Dual low response to acetylsalicylic acid and clopidogrel is associated with myonecrosis and stent thrombosis after coronary stent implantation. Am Heart J 2010;159:891-898.e1. [PMID: 20435201 DOI: 10.1016/j.ahj.2010.02.025] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.2] [Reference Citation Analysis]
301 Ahn SG, Yoon J, Sung JK, Lee JH, Lee JW, Youn YJ, Ahn MS, Kim JY, Yoo BS, Lee SH, Choe KH. Intravascular ultrasound-guided percutaneous coronary intervention improves the clinical outcome in patients undergoing multiple overlapping drug-eluting stents implantation. Korean Circ J 2013;43:231-8. [PMID: 23682282 DOI: 10.4070/kcj.2013.43.4.231] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
302 Shankarraman V, Davis-Gorman G, McDonagh PF, Caplan MR. Intracellular signaling controls endothelial cell prostacyclin secretion and regulation of blood clotting time. J Biomed Mater Res A 2012;100:3374-83. [PMID: 22767493 DOI: 10.1002/jbm.a.34266] [Reference Citation Analysis]
303 Camenzind E, Wijns W, Mauri L, Boersma E, Parikh K, Kurowski V, Gao R, Bode C, Greenwood JP, Gershlick A, O'Neill W, Serruys PW, Jorissen B, Steg PG; PROTECT Steering Committee and Investigators. Rationale and design of the Patient Related OuTcomes with Endeavor versus Cypher stenting Trial (PROTECT): randomized controlled trial comparing the incidence of stent thrombosis and clinical events after sirolimus or zotarolimus drug-eluting stent implantation. Am Heart J 2009;158:902-909.e5. [PMID: 19958855 DOI: 10.1016/j.ahj.2009.10.002] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
304 Du F, Zhou J. Vascular Intervention: From Angioplasty to Bioresorbable Vascular Scaffold. Adv Exp Med Biol 2018;1097:181-9. [PMID: 30315545 DOI: 10.1007/978-3-319-96445-4_9] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
305 Chung MJ, Hansen JD, Schulteis RD, Boggan JC, Jones WS, Povsic TJ, Roberts S, Krucoff MW, Rao SV. Understanding operator stent choice in the catheterization laboratory using a pre-procedure survey: Opportunities for quality improvement. Cardiovasc Revasc Med 2017;18:588-91. [PMID: 28529095 DOI: 10.1016/j.carrev.2017.05.004] [Reference Citation Analysis]
306 Seedial SM, Ghosh S, Saunders RS, Suwanabol PA, Shi X, Liu B, Kent KC. Local drug delivery to prevent restenosis. J Vasc Surg 2013;57:1403-14. [PMID: 23601595 DOI: 10.1016/j.jvs.2012.12.069] [Cited by in Crossref: 54] [Cited by in F6Publishing: 50] [Article Influence: 6.0] [Reference Citation Analysis]
307 Pandya SB, Kim YH, Meyers SN, Davidson CJ, Flaherty JD, Park DW, Mediratta A, Pieper K, Reyes E, Bonow RO, Park SJ, Beohar N. Drug-eluting versus bare-metal stents in unprotected left main coronary artery stenosis a meta-analysis. JACC Cardiovasc Interv 2010;3:602-11. [PMID: 20630453 DOI: 10.1016/j.jcin.2010.03.019] [Cited by in Crossref: 58] [Cited by in F6Publishing: 34] [Article Influence: 4.8] [Reference Citation Analysis]
308 Shetty R, Vivek G, Thakkar A, Mishra SS, Joseph V, Devraj MG, Tumkur A, Pai U. Experience with biodegradable polymer coated sirolimus-eluting coronary stent system in "real-life" percutaneous coronary intervention: 24-month data from the manipal-s registry. J Clin Diagn Res 2013;7:1959-63. [PMID: 24179909 DOI: 10.7860/JCDR/2013/5915.3369] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
309 Zhu J, Liu L, Zhu Z, Yang Z, Hu J, Ding F, Zhou Y, Su X, Ge J, Liu X, Tang L, He Y, Zhou G, Ji Z, Li Y, Pang W, Zhang R. A randomized comparison of a novel iopromide-based paclitaxel-coated balloon Shenqi versus SeQuent Please for the treatment of in-stent restenosis. Coron Artery Dis 2021;32:526-33. [PMID: 33229940 DOI: 10.1097/MCA.0000000000000994] [Reference Citation Analysis]
310 Sung SH, Chen TC, Cheng HM, Lee JC, Lang HC, Chen CH. Comparison of Clinical Outcomes in Patients Undergoing Coronary Intervention with Drug-Eluting Stents or Bare-Metal Stents: A Nationwide Population Study. Acta Cardiol Sin 2017;33:10-9. [PMID: 28115802 DOI: 10.6515/acs20160608a] [Cited by in F6Publishing: 12] [Reference Citation Analysis]
311 Chibana H, Kajimoto H, Ueno T, Yokoyama S, Sasaki KI, Ohtsuka M, Koiwaya H, Nakayoshi T, Mitsutake Y, Itaya N, Sasaki M, Fukumoto Y. Interleukin-1β is associated with coronary endothelial dysfunction in patients with mTOR-inhibitor-eluting stent implantation. Heart Vessels 2017;32:823-32. [PMID: 28116487 DOI: 10.1007/s00380-017-0947-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
312 Richelsen RK, Overvad TF, Jensen SE. Drug-Eluting Balloons in the Treatment of Coronary De Novo Lesions: A Comprehensive Review. Cardiol Ther 2016;5:133-60. [PMID: 27384194 DOI: 10.1007/s40119-016-0064-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
313 Marlevi D, Edelman ER. Vascular Lesion-Specific Drug Delivery Systems: JACC State-of-the-Art Review. J Am Coll Cardiol 2021;77:2413-31. [PMID: 33985687 DOI: 10.1016/j.jacc.2021.03.307] [Cited by in Crossref: 1] [Reference Citation Analysis]
314 Suna G, Wojakowski W, Lynch M, Barallobre-Barreiro J, Yin X, Mayr U, Baig F, Lu R, Fava M, Hayward R, Molenaar C, White SJ, Roleder T, Milewski KP, Gasior P, Buszman PP, Buszman P, Jahangiri M, Shanahan CM, Hill J, Mayr M. Extracellular Matrix Proteomics Reveals Interplay of Aggrecan and Aggrecanases in Vascular Remodeling of Stented Coronary Arteries. Circulation 2018;137:166-83. [PMID: 29030347 DOI: 10.1161/CIRCULATIONAHA.116.023381] [Cited by in Crossref: 41] [Cited by in F6Publishing: 26] [Article Influence: 8.2] [Reference Citation Analysis]
315 Naik BI, Keeley EC, Gress DR, Zuo Z. Case scenario: a patient on dual antiplatelet therapy with an intracranial hemorrhage after percutaneous coronary intervention. Anesthesiology 2014;121:644-53. [PMID: 24950163 DOI: 10.1097/ALN.0000000000000350] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
316 Zhao L, Zhu W, Zhang X, He D, Guo C. Effect of diabetes mellitus on long-term outcomes after repeat drug-eluting stent implantation for in-stent restenosis. BMC Cardiovasc Disord 2017;17:16. [PMID: 28061808 DOI: 10.1186/s12872-016-0445-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
317 Akin I, Bufe A, Schneider S, Reinecke H, Eckardt L, Richardt G, Burska D, Senges J, Kuck KH, Nienaber CA. Clinical outcomes in diabetic and non-diabetic patients with drug-eluting stents: results from the first phase of the prospective multicenter German DES.DE registry. Clin Res Cardiol 2010;99:393-400. [PMID: 20221833 DOI: 10.1007/s00392-010-0136-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
318 Satapathy SK, Vanatta JM, Helmick RA, Flowers A, Kedia SK, Jiang Y, Ali B, Eason J, Nair SP, Ibebuogu UN. Outcome of Liver Transplant Recipients With Revascularized Coronary Artery Disease: A Comparative Analysis With and Without Cardiovascular Risk Factors. Transplantation. 2017;101:793-803. [PMID: 28099403 DOI: 10.1097/tp.0000000000001647] [Cited by in Crossref: 27] [Cited by in F6Publishing: 9] [Article Influence: 5.4] [Reference Citation Analysis]
319 Numthavaj P, Thakkinstian A, Dejthevaporn C, Attia J. Corticosteroid and antiviral therapy for Bell’s palsy: a network meta-analysis. BMC Neurol. 2011;11:1. [PMID: 21208452 DOI: 10.1186/1471-2377-11-1] [Cited by in Crossref: 48] [Cited by in F6Publishing: 33] [Article Influence: 4.4] [Reference Citation Analysis]
320 Dalos D, Gangl C, Roth C, Krenn L, Scherzer S, Vertesich M, Lang I, Maurer G, Neunteufl T, Berger R, Delle-Karth G. Mechanical properties of the everolimus-eluting bioresorbable vascular scaffold compared to the metallic everolimus-eluting stent. BMC Cardiovasc Disord 2016;16:104. [PMID: 27225486 DOI: 10.1186/s12872-016-0296-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
321 Nassar H, Gotsman I, Gerganski P, Moseri M, Lotan C, Gotsman M. Cutting balloon angioplasty and stent implantation for aorto-ostial lesions: clinical outcome and 1-year follow-up. Clin Cardiol 2009;32:183-6. [PMID: 19353700 DOI: 10.1002/clc.20351] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
322 Bolinera SV, Tharaknath VR, Reddy SS, Polavarapu RS, Polavarapu A, Polavarapu N, Byrapaneni S, Gangasani S, Chilukuri M, Pamidimukkala V. Safety and performance of everolimus-eluting stents comprising of biodegradable polymers with ultrathin stent platforms. Minerva Med 2020;111:315-23. [PMID: 33032393 DOI: 10.23736/S0026-4806.20.06205-9] [Reference Citation Analysis]
323 Madigan M, Entabi F, Zuckerbraun B, Loughran P, Tzeng E. Delayed inhaled carbon monoxide mediates the regression of established neointimal lesions. J Vasc Surg 2015;61:1026-33. [PMID: 24418641 DOI: 10.1016/j.jvs.2013.11.072] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
324 Choi Y, Lim S, Lee KY, Park HW, Byeon J, Hwang BH, Kim JJ, Oh YS, Youn HJ, Jung WS, Seung KB, Chang K. Renin-angiotensin system blockade reduces cardiovascular events in nonheart failure, stable patients with prior coronary intervention. Coron Artery Dis 2018;29:451-8. [PMID: 29489465 DOI: 10.1097/MCA.0000000000000609] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
325 Rekik S, Wehrlin C, Jacq L, Bellemain A, Bernasconi F. [Instent rupture of a saphenous vein graft during percutaneous intervention successfully treated with a covered stent]. Ann Cardiol Angeiol (Paris) 2014;63:394-7. [PMID: 25223830 DOI: 10.1016/j.ancard.2014.08.013] [Reference Citation Analysis]
326 Teoh LK, Lee CN. The role of CABG in the era of drug-eluting stents: a surgeon's viewpoint. Heart Asia 2010;2:7-10. [PMID: 27325933 DOI: 10.1136/ha.2009.001727] [Reference Citation Analysis]
327 Dörr R. [Bypass surgery versus percutaneous coronary intervention in patients with diabetes mellitus]. Herz 2010;35:182-90. [PMID: 20467930 DOI: 10.1007/s00059-010-3342-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
328 Nakamura K, Keating JH, Edelman ER. Pathology of Endovascular Stents. Interv Cardiol Clin 2016;5:391-403. [PMID: 28582036 DOI: 10.1016/j.iccl.2016.02.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
329 Cola C, Brugaletta S, Martín Yuste V, Campos B, Angiolillo DJ, Sabaté M. Diabetes mellitus: a prothrombotic state implications for outcomes after coronary revascularization. Vasc Health Risk Manag 2009;5:101-19. [PMID: 19436654 DOI: 10.2147/vhrm.s4248] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
330 Aronson D, Edelman ER. Revascularization for coronary artery disease in diabetes mellitus: angioplasty, stents and coronary artery bypass grafting. Rev Endocr Metab Disord. 2010;11:75-86. [PMID: 20221852 DOI: 10.1007/s11154-010-9135-3] [Cited by in Crossref: 54] [Cited by in F6Publishing: 44] [Article Influence: 4.5] [Reference Citation Analysis]
331 Saia F, Marzocchi A, Branzi A. The safety of drug-eluting stents. Ther Adv Cardiovasc Dis 2008;2:43-52. [PMID: 19124407 DOI: 10.1177/1753944707088158] [Cited by in Crossref: 5] [Article Influence: 0.4] [Reference Citation Analysis]
332 Sabaté M. Sirolimus Versus Paclitaxel: Second Round. JACC Cardiovasc Interv 2022;15:780-2. [PMID: 35305907 DOI: 10.1016/j.jcin.2022.02.007] [Reference Citation Analysis]
333 Gundogan B, Tan A, Farhatnia Y, Alavijeh MS, Cui Z, Seifalian AM. Bioabsorbable stent quo vadis: a case for nano-theranostics. Theranostics 2014;4:514-33. [PMID: 24672583 DOI: 10.7150/thno.8137] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
334 Dola J, Morawiec B, Wańha W, Nowalany-Kozielska E, Wojakowski W, Kawecki D. Results of PCI with Drug-Eluting Stents in an All-Comer Population Depending on Vessel Diameter. J Clin Med 2020;9:E524. [PMID: 32075153 DOI: 10.3390/jcm9020524] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
335 Yin D, Li J, Yang YJ, Wang Y, Zhao YY, You SJ, Qiao SB, Xu B, Dou KF. Nine-year clinical outcomes of drug-eluting stents vs. bare metal stents for large coronary vessel lesions. J Geriatr Cardiol 2017;14:35-41. [PMID: 28270840 DOI: 10.11909/j.issn.1671-5411.2017.01.009] [Reference Citation Analysis]
336 Paramasivam G, Devasia T, Ubaid S, Shetty A, Nayak K, Pai U, Rao MS. In-stent restenosis of drug-eluting stents: clinical presentation and outcomes in a real-world scenario. Egypt Heart J 2019;71:28. [PMID: 31773342 DOI: 10.1186/s43044-019-0025-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
337 Raffoul J, Klein AJ. Dual antiplatelet therapy duration after the placement of a drug-eluting stent: what are the data? Curr Treat Options Cardiovasc Med 2015;17:367. [PMID: 25773476 DOI: 10.1007/s11936-015-0367-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
338 Trenk D, Neumann FJ. Drug-eluting coronary stents: as safe as bare-metal stents, but optimized antiplatelet therapy may further improve clinical outcome. Eur J Clin Pharmacol 2008;64:227-32. [PMID: 18075736 DOI: 10.1007/s00228-007-0434-x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
339 Ploegmakers MM, Viscaal AM, Finch L, Mayo NE, Brophy JM. The disutility of restenosis--the impact of repeat percutaneous coronary intervention on quality of life. Can J Cardiol 2010;26:197-200. [PMID: 20548981 DOI: 10.1016/s0828-282x(10)70399-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
340 Chisari A, Pistritto AM, Piccolo R, La Manna A, Danzi GB. The Ultimaster Biodegradable-Polymer Sirolimus-Eluting Stent: An Updated Review of Clinical Evidence. Int J Mol Sci 2016;17:E1490. [PMID: 27608017 DOI: 10.3390/ijms17091490] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
341 Ruedlinger J, Prado Y, Zambrano T, Saavedra N, Bobadilla B, Potthoff M, Pérez L, Lanas F, Salazar LA. CYP2C192 Polymorphism in Chilean Patients with In-Stent Restenosis Development and Controls. Biomed Res Int 2017;2017:5783719. [PMID: 28785581 DOI: 10.1155/2017/5783719] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
342 Mishra S, Ray S, Dalal JJ, Sawhney JP, Ramakrishnan S, Nair T, Iyengar SS, Bahl VK. Management standards for stable coronary artery disease in India. Indian Heart J 2016;68 Suppl 3:S31-49. [PMID: 28038722 DOI: 10.1016/j.ihj.2016.11.320] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
343 Bonaventura A, Montecucco F, Liberale L. Coronary stenting: A matter of revascularization. World J Cardiol 2017; 9(3): 207-211 [PMID: 28400917 DOI: 10.4330/wjc.v9.i3.207] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
344 Sun Q, Bai J, Lv R. Hedgehog/Gli1 signal pathway facilitates proliferation, invasion, and migration of cutaneous SCC through regulating VEGF. Tumour Biol 2016. [PMID: 27752995 DOI: 10.1007/s13277-016-5435-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
345 Tentzeris I, Jarai R, Farhan S, Wojta J, Schillinger M, Geppert A, Nürnberg M, Unger G, Huber K. Long-term outcome after drug-eluting stent implantation in comparison with bare metal stents: a single centre experience. Clin Res Cardiol 2011;100:191-200. [PMID: 20859742 DOI: 10.1007/s00392-010-0228-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
346 Wang PJ, Nezami FR, Gorji MB, Berti F, Petrini L, Wierzbicki T, Migliavacca F, Edelman ER. Effect of working environment and procedural strategies on mechanical performance of bioresorbable vascular scaffolds. Acta Biomater 2018;82:34-43. [PMID: 30342288 DOI: 10.1016/j.actbio.2018.10.020] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
347 Migita S, Kitano D, Li Y, Koyama Y, Shimodai-Yamada S, Onishi A, Fuchimoto D, Suzuki S, Nakamura Y, Matsuyama TA, Hirota S, Sakuma M, Tsujimoto M, Hirayama A, Okumura Y, Hao H. Pathological findings after third- and second-generation everolimus-eluting stent implantations in coronary arteries from autopsy cases and an atherosclerotic porcine model. Sci Rep 2021;11:6281. [PMID: 33737695 DOI: 10.1038/s41598-021-85740-2] [Reference Citation Analysis]
348 Bil J, Gil RJ, Kern A, Pawłowski T, Seweryniak P, Śliwiński Z. Novel sirolimus-eluting stent Prolim® with a biodegradable polymer in the all-comers population: one year clinical results with quantitative coronary angiography and optical coherence tomography analysis. BMC Cardiovasc Disord 2015;15:150. [PMID: 26573577 DOI: 10.1186/s12872-015-0139-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
349 Ahmed K, Jeong MH, Chakraborty R, Hong YJ, Sim DS, Ahmed S, Hwang SH, Lee MG, Park KH, Kim JH, Ahn Y, Cho MC, Kim CJ, Kim YJ, Park JC, Kang JC; Korea Acute Myocardial Infarction Registry Investigators. Safety and efficacy of overlapping homogenous drug-eluting stents in patients with acute myocardial infarction: results from Korea Acute Myocardial Infarction Registry. J Korean Med Sci 2012;27:1339-46. [PMID: 23166415 DOI: 10.3346/jkms.2012.27.11.1339] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
350 Möllmann H, Szardien S, Kempfert J, Nef H, Liebetrau C, Walther T, Hamm C. [Myocardial revascularization]. Internist (Berl) 2012;53:1063-75; quiz 1076-8. [PMID: 22836917 DOI: 10.1007/s00108-012-3035-4] [Reference Citation Analysis]
351 Seob Lim K, Park JK, Ho Jeong M, Ho Bae I, Sung Park D, Won Shim J, Ha Kim J, Kuk Kim H, Soo Kim S, Sun Sim D, Joon Hong Y, Han Kim J, Ahn Y. Anti-Inflammatory Effect of Gallic Acid-Eluting Stent in a Porcine Coronary Restenosis Model. Acta Cardiol Sin 2018;34:224-32. [PMID: 29844643 DOI: 10.6515/ACS.201805_34(3).20171204A] [Cited by in F6Publishing: 5] [Reference Citation Analysis]